Aclaris Therapeutics, Inc DEF 14A, filed Apr 20, 2023
Aclaris Therapeutics, Inc. (ACRS)
About this DEF 14A
Aclaris Therapeutics, Inc filed this DEF 14A on April 20, 2023.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No. __)
Filed by the Registrant ☒
Filed by a Party other than the Registrant ☐
Check the appropriate box:
☐ | Preliminary Proxy Statement |
☐ | Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
☒ | Definitive Proxy Statement |
☐ | Definitive Additional Materials |
☐ | Soliciting Material Under §240.14a-12 |
| |
(Name of Registrant as Specified In Its Charter) | ||
(Name of Person(s) Filing Proxy Statement, if other than the Registrant) |
| |
Payment of Filing Fee (Check all boxes that apply): | ||
☒ | No fee required | |
☐ | Fee paid previously with preliminary materials | |
☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 | |
ACLARIS THERAPEUTICS, INC.
640 Lee Road, Suite 200
Wayne, Pennsylvania 19087
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
To Be Held on June 1, 2023
Dear Stockholder:
You are cordially invited to attend the Annual Meeting of Stockholders of Aclaris Therapeutics, Inc., a Delaware corporation (the “Company”). The Annual Meeting will be held on Thursday, June 1, 2023 at 9:00 a.m. Eastern Time. The Annual Meeting will be a virtual stockholder meeting through which you can listen to the meeting, submit questions and vote online. The Annual Meeting can be accessed by visiting www.virtualshareholdermeeting.com/ACRS2023 and entering your 16-digit control number (included in the Notice of Internet Availability of Proxy Materials that will be mailed to you). You will not be able to attend the Annual Meeting in person. The purpose of the Annual Meeting will be the following:
| 1. | To elect the three nominees for director named herein to hold office until the 2026 Annual Meeting of Stockholders. |
| 2. | To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the proxy statement accompanying this Notice. |
| 3. | To approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 100,000,000 to 200,000,000 shares. |
| 4. | To ratify the selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023. |
| 5. | To conduct any other business properly brought before the meeting. |
These items of business are more fully described in the proxy statement accompanying this Notice.
The record date for the Annual Meeting is April 11, 2023. Only stockholders of record at the close of business on that date may vote at the meeting or any postponement or adjournment thereof.
We have elected to provide access to our proxy materials over the internet under the Securities and Exchange Commission’s “notice and access” rules. As a result, we are mailing to our stockholders a Notice of Internet Availability of Proxy Materials instead of paper copies of the proxy statement and our 2022 Annual Report. The notice contains instructions on how to access those documents over the internet. The notice also contains instructions on how stockholders can receive a paper copy of our proxy materials, including the proxy statement, our 2022 Annual Report and a form of proxy card or voting instruction form. We believe that providing our proxy materials over the internet increases the ability of our stockholders to connect with the information they need, while reducing the environmental impact and cost of our Annual Meeting.
By Order of the Board of Directors
Matthew Rothman
Secretary
Wayne, Pennsylvania
April 20, 2023
You are cordially invited to attend the meeting online. Whether or not you expect to attend the meeting, please complete, date, sign and return the proxy mailed to you, or vote over the telephone or on the internet as instructed in these materials, as promptly as possible in order to ensure your representation at the meeting. Voting instructions are provided in the Notice of Internet Availability of Proxy Materials, or, if you receive a paper proxy card by mail, the instructions are printed on your proxy card and included in the accompanying proxy statement. Even if you have voted by proxy, you may still vote online if you attend the meeting. To vote online at the Annual Meeting, please follow the instructions at www.virtualshareholdermeeting.com/ACRS2023. You will need the 16-digit control number, which is included in the Notice of Internet Availability of Proxy Materials that will be mailed to you. |
ACLARIS THERAPEUTICS, INC.
640 Lee Road, Suite 200
Wayne, Pennsylvania 19087
PROXY STATEMENT
FOR THE 2023 ANNUAL MEETING OF STOCKHOLDERS
To be held on June 1, 2023
QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING
Why did I receive a Notice of Internet Availability of Proxy Materials on the internet instead of a full set of Proxy Materials?
Pursuant to rules adopted by the Securities and Exchange Commission (the “SEC”), we have elected to provide access to our Proxy Materials (defined below) over the internet. Accordingly, on or about April 20, 2023, we are sending you a Notice of Internet Availability of Proxy Materials (the “Notice of Internet Availability”) because the Board of Directors (the “Board”) of Aclaris Therapeutics, Inc. (sometimes referred to as the “Company” or “Aclaris”) is soliciting your proxy to vote at the 2023 Annual Meeting of Stockholders, including at any adjournments or postponements thereof (the “Annual Meeting”). The Notice of 2023 Annual Meeting of Stockholders (“Notice of Annual Meeting”), this proxy statement and proxy card or, for shares held in street name (held for your account by a broker or other nominee), voting instruction form, and our 2022 Annual Report (collectively the “Proxy Materials”) are available to stockholders on the internet.
The Notice of Internet Availability will provide instructions as to how stockholders may access and review the Proxy Materials on the website referred to in the Notice of Internet Availability or, alternatively, how to request that a copy of the Proxy Materials, including a proxy card, be sent to them by mail. The Notice of Internet Availability will also provide voting instructions. Please note that, while our Proxy Materials are available at the website referenced in the Notice of Internet Availability, and our Notice of Annual Meeting, proxy statement and Annual Report on Form 10-K for the year ended December 31, 2022 are available on our website, no other information contained on either website is incorporated by reference in or considered to be a part of this document.
We intend to mail the Notice of Internet Availability on or about April 20, 2023 to all stockholders of record entitled to vote at the Annual Meeting. The Proxy Materials will be made available to stockholders on the internet on the same date.
Will I receive any Proxy Materials by mail?
Other than the Notice of Internet Availability, you will not receive any Proxy Materials via mail unless (1) you request a printed copy of the Proxy Materials in accordance with the instructions set forth in the Notice of Internet Availability or (2) we elect, in our discretion, to send you a proxy card and a second Notice of Internet Availability.
How do I attend the Annual Meeting?
The meeting will be held on Thursday, June 1, 2023 at 9:00 a.m. Eastern Time. The Annual Meeting will be a virtual stockholder meeting through which you can listen to the meeting, submit questions and vote online. The Annual Meeting can be accessed by visiting www.virtualshareholdermeeting.com/ACRS2023 and entering your 16-digit control number which is included in the Notice of Internet Availability that will be mailed to you. The virtual meeting platform is fully supported across browsers and devices running the most updated version of applicable software and plugins. Participants should ensure that they have a strong internet connection wherever they intend to participate in the meeting. You will not be able to attend the Annual Meeting in person.
Whether or not you participate in the Annual Meeting, it is important that you vote your shares.
We recommend that you log in a few minutes before the Annual Meeting on June 1, 2023 to ensure you are logged in when the meeting starts. Online check-in will begin at 8:55 a.m. Eastern Time.
1
Why is the Annual Meeting a virtual, online meeting?
We have decided to hold a virtual meeting to facilitate stockholder participation in the Annual Meeting. Stockholders attending the virtual meeting will be afforded the same rights and opportunities to participate as they would at an in-person meeting.
Information on how to vote online during the Annual Meeting is discussed below.
Can I ask questions at the Annual Meeting?
Only stockholders of record as of the record date for the Annual Meeting and their proxy holders may submit questions or comments.
If you would like to submit a question, you may do so by joining the virtual Annual Meeting at www.virtualshareholdermeeting.com/ACRS2023 and typing your question in the box in the Annual Meeting portal.
To help ensure that we have a productive and efficient meeting, and in fairness to all stockholders in attendance, you will also find posted our rules of conduct for the Annual Meeting when you log in prior to its start. In accordance with the rules of conduct, we ask that you limit your remarks to one brief question or comment that is relevant to the Annual Meeting or our business and that remarks are respectful of your fellow stockholders and meeting participants. Questions may be grouped by topic by our management with a representative question read aloud and answered. In addition, questions may be ruled as out of order if they are, among other things, irrelevant to our business, related to pending or threatened litigation, disorderly, repetitious of statements already made, or in furtherance of the speaker’s own personal, political or business interests. Questions will be addressed in the Q&A portion of the Annual Meeting, as time permits.
What if I need technical assistance accessing or participating in the virtual Annual Meeting?
If you encounter any difficulties accessing the virtual Annual Meeting during the check-in or meeting time, please call the technical support number that will be posted on the Virtual Stockholder Meeting login page. Technical support will be available starting at 8:55 a.m. Eastern Time on June 1, 2023.
Who can vote at the Annual Meeting?
Only stockholders of record at the close of business on April 11, 2023 will be entitled to vote at the Annual Meeting. On this record date, there were 70,679,395 shares of common stock outstanding and entitled to vote.
Stockholder of Record: Shares Registered in Your Name
If at the close of business on April 11, 2023 your shares were registered directly in your name with Aclaris Therapeutics, Inc.’s transfer agent, Broadridge Corporate Issuer Solutions, Inc., then you are a stockholder of record. As a stockholder of record, you may vote at the meeting or vote by proxy. Whether or not you plan to attend the meeting, we urge you to fill out and return a proxy card that you may request or that we may elect to deliver at a later time, or vote by proxy over the telephone or on the internet as instructed below to ensure your vote is counted.
Beneficial Owner: Shares Registered in the Name of a Broker or Bank
If at the close of business on April 11, 2023 your shares were held, not in your name, but rather in an account at a brokerage firm, bank or other similar organization, then you are the beneficial owner of shares held in “street name” and the Notice of Internet Availability is being forwarded to you by that organization. The organization holding your account is considered to be the stockholder of record for purposes of voting at the Annual Meeting. As a beneficial owner, you have the right to direct your broker, bank or other agent regarding how to vote the shares in your account. You are also invited to attend the Annual Meeting via the internet. Whether or not you plan to attend the Annual Meeting via the internet, we urge you to fill out and return a proxy card or vote by proxy over the telephone or on the internet as instructed below to ensure your vote is counted.
2
Will a list of stockholders entitled to vote at the Annual Meeting be available?
Our list of stockholders as of April 11, 2023 will be available for inspection at our corporate office for the 10 days prior to the Annual Meeting. If you want to inspect the stockholder list, call our office at 484-324-7933 to speak with our Investor Relations department to schedule an appointment.
What am I voting on?
There are four matters scheduled for a vote:
| ● | Election of three directors to hold office until the 2026 Annual Meeting of Stockholders (Proposal 1); |
| ● | Advisory approval of the compensation of the Company’s named executive officers, as disclosed in this proxy statement in accordance with SEC rules (Proposal 2); |
| ● | Approval of an amendment to our Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 100,000,000 shares to 200,000,000 shares (Proposal 3); and |
| ● | Ratification of selection by the Audit Committee of the Board of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2023 (Proposal 4). |
What if another matter is properly brought before the meeting?
The Board knows of no other matters that will be presented for consideration at the Annual Meeting. If any other matters are properly brought before the meeting, it is the intention of the persons named in the accompanying proxy to vote on those matters in accordance with their best judgment.
How do I vote?
For Proposal 1, you may either vote “For” all the nominees to the Board or you may “Withhold” your vote for any nominee you specify. For Proposals 2, 3 and 4, you may vote “For” or “Against” or abstain from voting.
The procedures for voting are fairly simple:
Stockholder of Record: Shares Registered in Your Name
If you are a stockholder of record, you may vote at the Annual Meeting or vote by proxy in one of three ways: online, by telephone or using a proxy card that you may request or that we may elect to deliver at a later time. Whether or not you plan to attend the meeting via the internet, we urge you to vote by proxy to ensure your vote is counted. You may still attend the meeting via the internet and vote during the meeting even if you have already voted by proxy.
| ● | To vote through the internet before the Annual Meeting, go to www.proxyvote.com to complete an electronic proxy card. Please have your Notice of Internet Availability in hand when you access the web site and then follow the instructions. If you choose to vote through the internet before the Annual Meeting, your vote must be received by 11:59 p.m. Eastern Time on May 31, 2023 to be counted. |
| ● | You may attend the Annual Meeting via the internet and vote during the Annual Meeting. The Annual Meeting can be accessed by visiting www.virtualshareholdermeeting.com/ACRS2023 and entering your 16-digit control number which is included in the Notice of Internet Availability that will be mailed to you. Please have your notice in hand when you access the website and then follow the instructions. |
3
| ● | To vote over the telephone, dial toll-free 1-800-690-6903 using a touch-tone phone and follow the recorded instructions. You will be asked to provide the company number and control number from the Notice of Internet Availability. Your telephone vote must be received by 11:59 p.m. Eastern Time on May 31, 2023 to be counted. |
| ● | To vote using the proxy card, simply complete, sign and date the proxy card that may be delivered and return it promptly in the envelope provided. If you return your signed proxy card to us before the Annual Meeting, we will vote your shares as you direct. |
Beneficial Owner: Shares Registered in the Name of Broker or Bank
If you are a beneficial owner of shares registered in the name of your broker, bank, or other agent, you should have received a notice containing voting instructions from that organization rather than from us. Simply follow the instructions in the notice to ensure that your vote is counted. Alternatively, you may vote by telephone or on the internet as instructed by your broker or bank. To vote online at the Annual Meeting, please follow the instructions at www.virtualshareholdermeeting.com/ACRS2023. You will need the 16-digit control number, which is included in the Notice of Internet Availability that will be mailed to you. Whether or not you plan to attend the meeting, we urge you to vote by proxy to ensure your vote is counted. You may still attend the Annual Meeting and vote online even if you have already voted by proxy.
Internet proxy voting is provided to allow you to vote your shares online, with procedures designed to ensure the authenticity and correctness of your proxy vote instructions. However, please be aware that you must bear any costs associated with your internet access, such as usage charges from internet access providers and telephone companies. |
How many votes do I have?
On each matter to be voted upon, you have one vote for each share of common stock you own at the close of business on April 11, 2023.
If I am a stockholder of record and I do not vote, or if I return a proxy card or otherwise vote without giving specific voting instructions, what happens?
If you are a stockholder of record and do not vote by completing a proxy card, by telephone, or through the internet either before or during the Annual Meeting, your shares will not be voted.
If you return a signed and dated proxy card or otherwise vote without marking voting selections, your shares will be voted, as applicable, “For” the election of the nominees for director, “For” the advisory approval of the compensation of our named executive officers, “For” the charter amendment to increase the number of authorized shares of common stock, and “For” the ratification of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023. If any other matter is properly presented at the meeting, your proxyholder (one of the individuals named on your proxy card) will vote your shares using his or her best judgment.
If I am a beneficial owner of shares held in street name and I do not provide my broker or bank with voting instructions, what happens?
If you are a beneficial owner of shares held in street name and you do not instruct your broker, bank or other agent how to vote your shares, your broker, bank or other agent may still be able to vote your shares in its discretion. In this regard, under the rules of the New York Stock Exchange (NYSE), brokers, banks and other securities intermediaries that are subject to NYSE rules may use their discretion to vote your “uninstructed” shares with respect to matters considered to be “routine” under NYSE rules, but not with respect to “non-routine” matters. In this regard, Proposals 1 and 2 are considered to be “non-routine” under NYSE rules, meaning that your broker may not vote your shares on those proposals in the absence of your voting instructions. However, the NYSE has advised us that Proposals 3 and 4 are considered to be
4
“routine” matters under NYSE rules, meaning that if you do not return voting instructions to your broker by its deadline, your shares may be voted by your broker in its discretion on Proposals 3 and 4.
If you a beneficial owner of shares held in street name, in order to ensure your shares are voted in the way you would prefer, you must provide voting instructions to your broker, bank or other agent by the deadline provided in the materials you receive from your broker, bank or other agent or vote online at the Annual Meeting.
Who is paying for this proxy solicitation?
We will pay for the entire cost of soliciting proxies. In addition to the Proxy Materials, our directors and employees may also solicit proxies by telephone or by other means of communication. Directors and employees will not be paid any additional compensation for soliciting proxies. We may also reimburse brokerage firms, banks and other agents for the cost of forwarding Proxy Materials to beneficial owners.
What does it mean if I receive more than one Notice of Internet Availability?
If you receive more than one Notice of Internet Availability, your shares may be registered in more than one name or in different accounts. Please follow the voting instructions on the notices to ensure that all of your shares are voted.
Can I change my vote after submitting my proxy?
Stockholder of Record: Shares Registered in Your Name
Yes. You can revoke your proxy at any time before the final vote at the meeting. If you are the record holder of your shares, you may revoke your proxy in any one of the following ways:
| ● | You may grant a subsequent proxy by telephone or on the internet. |
| ● | You may submit another properly completed proxy card with a later date. |
| ● | You may send a timely written notice that you are revoking your proxy to Aclaris Therapeutics, Inc.’s Secretary at 640 Lee Road, Suite 200, Wayne, Pennsylvania 19087. |
| ● | You may attend the Annual Meeting via the internet and vote online. Simply attending the meeting will not, by itself, revoke your proxy. |
Your most current proxy card or telephone or internet proxy is the one that is counted.
Beneficial Owner: Shares Registered in the Name of Broker or Bank
If your shares are held by your broker, bank or other agent, you should follow the instructions provided by that organization or vote online at the Annual Meeting.
When are stockholder proposals due for next year’s Annual Meeting?
To be considered for inclusion in next year’s proxy materials, your proposal must be submitted in writing by December 22, 2023, to our Corporate Secretary at 640 Lee Road, Suite 200, Wayne, Pennsylvania 19087. If you wish to nominate an individual for election at, or bring business other than through a stockholder proposal before, the 2024 Annual Meeting of Stockholders, you must deliver your notice to our Corporate Secretary at the address above between February 2, 2024 and March 3, 2024; provided, however that if next year’s annual meeting is advanced more than 30 days prior to or delayed by more than 30 days after June 1, 2024, your proposal must be submitted not earlier than the close of business on the 120th day prior to such annual meeting and not later than the close of business on the later of the 90th day prior to such annual meeting or the tenth day following the day on which public announcement of the date of such meeting is first made.
5
Your notice to the Corporate Secretary must set forth information specified in our amended and restated bylaws, including your name and address and the class and number of shares of our stock that you beneficially own. In addition, stockholders who intend to solicit proxies in support of director nominees other than the Board’s nominees must also comply with the additional requirements of Rule 14a-19(b).
If you propose to bring business before an annual meeting other than a director nomination, your notice must also include, as to each matter proposed, the following: (1) a brief description of the business desired to be brought before the annual meeting and the reasons for conducting that business at the annual meeting and (2) any material interest you have in that business. If you propose to nominate an individual for election as a director, your notice must also include, as to each person you propose to nominate for election as a director, the following: (1) the name, age, business address and residence address of the person, (2) the principal occupation or employment of the person, (3) the class and number of shares of our stock that are owned of record and beneficially owned by the person, (4) the date or dates on which the shares were acquired and the investment intent of the acquisition and (5) any other information concerning the person as would be required to be disclosed in a proxy statement soliciting proxies for the election of that person as a director in an election contest (even if an election contest is not involved), or that is otherwise required to be disclosed pursuant to Section 14 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations promulgated under the Exchange Act, including the person’s written consent to being named as a nominee and to serving as a director if elected. We may require any proposed nominee to furnish other information as we may reasonably require to determine the eligibility of the proposed nominee to serve as an independent director or that could be material to a reasonable stockholder’s understanding of the independence, or lack of independence, of the proposed nominee.
For more information, and for more detailed requirements, please refer to our amended and restated bylaws, filed as an exhibit to our most recent Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on February 23, 2023.
How are votes counted?
Votes will be counted by the inspector of election appointed for the meeting.
What are “broker non-votes”?
A “broker non-vote” occurs when your broker submits a proxy for the meeting with respect to “routine” matters but does not vote on “non-routine” matters because you did not provide voting instructions on these matters. These unvoted shares with respect to the “non-routine” matters are counted as “broker non-votes.” Proposals 1 and 2 are considered to be “non-routine” under NYSE rules, and we therefore expect broker non-votes to exist in connection with these proposals.
As a reminder, if you a beneficial owner of shares held in street name, in order to ensure your shares are voted in the way you would prefer, you must provide voting instructions to your broker, bank or other agent by the deadline provided in the materials you receive from your broker, bank or other agent or vote online at the Annual Meeting.
6
How many votes are needed to approve each proposal?
The following table summarizes the minimum vote needed to approve each proposal and the effect of abstentions and broker non-votes.
Proposal |
| Proposal Description |
| Vote Required for Approval |
| Effect of |
| Effect of |
1 | | Election of Directors | | Nominees receiving the most “For” votes | | Not applicable | | No effect |
2 | | Advisory vote to approve compensation of our named executive officers | | “For” votes from holders of a majority of the shares having voting power present or represented by proxy at the Annual Meeting | | Against | | No effect |
3 | | Charter amendment to increase authorized shares of common stock | | “For” votes from holders of a majority of the outstanding shares entitled to vote | | Against | | Against (1) |
4 | | Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2023 | | “For” votes from holders of a majority of the shares having voting power present or represented by proxy at the Annual Meeting | | Against | | Brokers have discretion to vote(1) |
| (1) | This proposal is considered a “routine” matter under NYSE rules. Accordingly, if you hold your shares in “street name” and do not provide voting instructions to your broker, bank or other agent that holds your shares, your broker, bank or other agent has discretionary authority under NYSE rules to vote your shares on this proposal. |
What is the quorum requirement?
A quorum of stockholders is necessary to hold a valid meeting. A quorum will be present if stockholders holding at least a majority of the outstanding shares entitled to vote are present at the Annual Meeting or represented by proxy. At the close of business on the record date, there were 70,679,395 shares outstanding and entitled to vote. Thus, the holders of 35,339,698 shares must be present or represented by proxy at the Annual Meeting to have a quorum.
Abstentions and broker non-votes will be counted towards the quorum requirement. If there is no quorum, either the chair of the Annual Meeting or the holders of a majority of shares present at the meeting or represented by proxy may adjourn the Annual Meeting to another date.
How can I find out the results of the voting at the Annual Meeting?
Preliminary voting results will be announced at the Annual Meeting. In addition, final voting results will be published in a current report on Form 8-K that we expect to file within four business days after the Annual Meeting. If final voting results are not available to us in time to file a Form 8-K within four business days after the meeting, we intend to file a Form 8‑K to publish preliminary results and, within four business days after the final results are known to us, file an additional Form 8-K to publish the final results.
7
PROPOSAL 1
ELECTION OF DIRECTORS
Our Board is divided into three classes. Each class consists, as nearly as possible, of one-third of the total number of directors, and each class has a three-year term. Vacancies on the Board may be filled only by persons elected by a majority of the remaining directors. A director elected by the Board to fill a vacancy in a class, including vacancies created by an increase in the number of directors, shall serve for the remainder of the full term of that class and until the director’s successor is duly elected and qualified.
The Board presently has ten members. There are three directors in the class whose term of office expires in 2023: Anand Mehra, M.D., Andrew Powell, Esq., and Maxine Gowen, Ph.D. Each of the nominees listed below is currently a director of the Company who was previously elected by the stockholders. If elected at the Annual Meeting, each of these nominees would serve until the 2026 Annual Meeting of Stockholders and until his or her successor has been duly elected and qualified, or, if sooner, until the director’s death, resignation or removal. It is our policy to invite and encourage directors and nominees for director to attend the Annual Meeting. Five of the nine then serving directors attended the 2022 Annual Meeting of Stockholders.
Directors are elected by a plurality of the votes of the holders of shares present or represented by proxy and entitled to vote on the election of directors at the Annual Meeting. Accordingly, the three nominees receiving the highest number of affirmative votes will be elected. Shares represented by executed proxies will be voted, if authority to do so is not withheld, for the election of the nominees named below. If any nominee becomes unavailable for election as a result of an unexpected occurrence, shares that would have been voted for that nominee may instead be voted for the election of a substitute nominee proposed by our Board. Each person nominated for election has agreed to serve if elected, and we have no reason to believe that any nominee will be unable to serve.
The Nominating and Corporate Governance Committee of our Board seeks to assemble a board that, as a whole, possesses the appropriate balance of professional and industry knowledge, financial expertise and high-level management experience necessary to oversee and direct our business. To that end, the Nominating and Corporate Governance Committee has identified and evaluated the nominees in the broader context of the Board’s overall composition, with the goal of recruiting members who complement and strengthen the skills of other members and who also exhibit integrity, collegiality, sound business judgment and other qualities that the Nominating and Corporate Governance Committee views as critical to effective functioning of the Board.
The biographies below include information, as of the date of this proxy statement, regarding the specific and particular experience, qualifications, attributes or skills of each nominee that led the Nominating and Corporate Governance Committee to recommend that person as a nominee for director. However, each member of the committee may have a variety of reasons why he or she believes a particular person would be an appropriate nominee for the Board, and these views may differ from the views of other members.
NOMINEES FOR ELECTION FOR A THREE-YEAR TERM EXPIRING AT THE 2026 ANNUAL MEETING
Anand Mehra, M.D., age 47
Anand Mehra, M.D. has served as a member of our Board since 2014. Dr. Mehra joined Sofinnova Investments, Inc. (fka Sofinnova Ventures, Inc.), a biotech investment firm, in 2007 and served as a managing general partner until January 2020. Prior to joining Sofinnova, Dr. Mehra worked in J.P. Morgan’s private equity and venture capital group, and before that, Dr. Mehra was a consultant in McKinsey & Company’s pharmaceutical practice. Dr. Mehra currently serves as the chairman of the board of directors of the publicly held company Merus N.V. Within the past five years, he also served on the board of directors of the pharmaceutical company Spark Therapeutics, Inc. Dr. Mehra received a B.A. degree in political philosophy from the University of Virginia and an M.D. degree from Columbia University’s College of Physicians and Surgeons. Our Board believes that Dr. Mehra’s extensive experience in the life sciences industry, his service on the boards of directors of other public life sciences companies and his extensive leadership experience qualify him to serve as a director of our company.
8
Andrew Powell, Esq., age 65
Andrew Powell is an independent consultant who has served as a member of our Board since 2017. Within the past five years, Mr. Powell served on the boards of directors of Silverback Therapeutics, Inc. (now known as ARS Pharmaceuticals, Inc.), Landec Corporation (now known as Lifecore Biomedical, Inc.), Synthorx Inc., a biopharmaceutical company acquired by Sanofi Aventis in January 2020, and Motif Bio plc. Mr. Powell served as Senior Vice President, General Counsel and Corporate Secretary of Medivation, Inc. from 2015 until 2016, when the company was acquired by Pfizer, Inc. Mr. Powell received a B.A. degree from the University of North Carolina at Chapel Hill and a J.D. from Stanford Law School. Our Board believes that Mr. Powell’s unique expertise in the areas of governance, compliance, intellectual property, drug development, licensing and mergers and acquisitions qualifies him to serve as a director of our company.
Maxine Gowen, Ph.D., age 65
Maxine Gowen has served as a member of our Board since July 2019. Dr. Gowen joined TamuroBio Inc., a biotechnology company, in August 2019, and served as its part-time Chief Executive Officer until December 2021. Dr. Gowen founded Trevena, Inc., a publicly held biopharmaceutical company, and served as its President and Chief Executive Officer from 2007 until October 2018. Prior to this, Dr. Gowen held a variety of leadership roles at GlaxoSmithKline (GSK) over a period of fifteen years. Dr. Gowen was previously President and Managing Partner at SR One, the venture capital subsidiary of GSK, where she led its investments in, and served on the board of directors of, numerous companies. Until 2002, Dr. Gowen was Vice President, Drug Discovery, Musculoskeletal Diseases at GSK, responsible for drug discovery and early development for osteoporosis, arthritis and metastatic bone disease. Dr. Gowen held a tenured academic position in the School of Pharmacology, University of Bath, UK from 1989 to 1992. Dr. Gowen currently serves on the boards of directors of the publicly held companies Aceragen, Inc. (formerly known as Idera Pharmaceuticals, Inc.), Merus N.V. and Passage Bio, Inc. Within the past five years, Dr. Gowen served as a director of the publicly held companies Trevena, Inc. and Akebia Therapeutics, Inc. Dr. Gowen served on the board of the national biotechnology industry association, BIO, from 2008 to 2018. Dr. Gowen received a B.Sc. in biochemistry from the University of Bristol, UK, then received a Ph.D. in cell biology from the University of Sheffield, UK, and received an M.B.A from The Wharton School of the University of Pennsylvania. Dr. Gowen also received a D.Sc. from the University of Bath, UK. Our Board believes that Dr. Gowen’s extensive leadership experience with pharmaceutical and biotechnology companies qualifies her to serve as a director of our company.
THE BOARD OF DIRECTORS RECOMMENDS
A VOTE IN FAVOR OF EACH NAMED NOMINEE.
DIRECTORS CONTINUING IN OFFICE UNTIL THE 2024 ANNUAL MEETING
Christopher Molineaux, age 57
Christopher Molineaux has served as Lead Independent Director of our Board since January 2023, having previously served as Chair since June 2019. He has served as a member of our Board since 2014. Since 2010, Mr. Molineaux has served as President and Chief Executive Officer of Life Sciences Pennsylvania, formerly Pennsylvania Bio, a pharmaceutical and biotech industry advocacy organization, and previously served as its Senior Vice President, Membership Services. Mr. Molineaux previously served as worldwide Vice President of Pharmaceutical Communications and Public Affairs for Johnson & Johnson, a global healthcare company. Mr. Molineaux also served as Vice President for Public Affairs at the Pharmaceutical Research and Manufacturers of America (PhRMA). He received a B.A. degree from the College of the Holy Cross. Our Board believes that Mr. Molineaux’s substantial pharmaceutical and biotechnology industry experience qualifies him to serve as a director of our company.
Bryan Reasons, age 55
Bryan Reasons has served as a member of our Board since April 2018. Since March 2019, Mr. Reasons has served as Executive Vice President and Chief Financial Officer of Mallinckrodt plc, a global specialty pharmaceutical company. Mr. Reasons served as Chief Financial Officer of Amneal Pharmaceuticals, Inc., a generics and specialty pharmaceutical
9
company, from May 2018 until January 2019 and as Senior Vice President, Finance and Chief Financial Officer of Impax Laboratories, Inc., a specialty pharmaceutical company, from 2012 until its acquisition by Amneal in May 2018. Mr. Reasons previously held various finance positions at Cephalon, Inc., a biopharmaceutical company, Teva Pharmaceutical Industries Ltd., a global pharmaceutical company, E. I. du Pont de Nemours and Company, and PricewaterhouseCoopers LLP, an independent registered public accounting firm. Mr. Reasons currently serves on the board of directors and on the audit committee of Societal CMDO (formerly known as Recro Pharma, Inc.), a publicly held specialty pharmaceutical company. Mr. Reasons received a B.S. degree in accounting from The Pennsylvania State University and an M.B.A. degree from Widener University. He is a certified public accountant in the Commonwealth of Pennsylvania. Our Board believes that Mr. Reasons’ extensive experience in the pharmaceutical industry, including his experience in senior leadership positions at a number of large pharmaceutical companies, as well as his expertise in financial and accounting matters, qualifies him to serve as a director of our company.
Vincent Milano, age 59
Vincent Milano has served as a member of our Board since January 2020. Mr. Milano was appointed Chair of the Board of Aceragen, Inc. (formerly known as Idera Pharmaceuticals, Inc.), a publicly held biopharmaceutical company, in 2022, having previously served as Idera’s President and Chief Executive Officer and a member of Idera’s board of directors since 2014. From 1996 to 2014, Mr. Milano served in increasingly senior roles at ViroPharma Inc., a pharmaceutical company acquired by Shire plc in 2014, most recently as Chairman, President and Chief Executive Officer from 2008 to 2014. From 1985 to 1996, Mr. Milano served in increasingly senior roles, most recently as a senior manager, at KPMG LLP, an independent registered public accounting firm. Mr. Milano currently serves on the boards of directors of BioCryst Pharmaceuticals, Inc., a publicly held company, and Life Sciences Cares Philadelphia, a non-profit organization. Within the past five years, Mr. Milano served on the boards of directors of the publicly held companies Spark Therapeutics, Inc. and Vanda Pharmaceuticals Inc., and VenatoRx Pharmaceuticals, Inc., a privately held company. Mr. Milano received a B.S. degree in Accounting from Rider College. Our Board believes that Mr. Milano’s extensive leadership experience with pharmaceutical and biotechnology companies qualifies him to serve as a director of our company.
DIRECTORS CONTINUING IN OFFICE UNTIL THE 2025 ANNUAL MEETING
Douglas Manion, M.D., FRCP(C), age 62
Douglas Manion, M.D., FRCP (C), has served as our Chief Executive Officer and President and as a member of our Board since January 2023. He joined our company in August 2022 as President and Chief Operating Officer. Prior to joining our company, Dr. Manion served as Executive Vice President of Research & Development of Arena Pharmaceuticals, Inc., a biopharmaceutical company, from July 2021 until its acquisition by Pfizer Inc. in March 2022. Dr. Manion previously served as Chief Executive Officer of Global BioShield, a not-for-profit company developing immunotherapies for COVID, from January to July 2021. He also served as Chief Executive Officer of Kleo Pharmaceuticals, Inc., an immuno-oncology company, from 2017 until its acquisition by Biohaven Pharmaceutical Holding Company Ltd. in January 2021. Between 2005 and 2016, Dr. Manion served in roles of increasing responsibility at Bristol-Myers Squibb (BMS), mostly recently as Senior Vice President, Head of Specialty Development and Head of R&D China and Japan. During his tenure at BMS, he held leadership roles overseeing global clinical research, clinical development, pharmacovigilance and biostatistics across various therapeutic areas, including virology, immunology, neurology, cardiology, metabolic diseases, genetically-defined diseases and fibrosis. Dr. Manion’s previous biopharmaceutical experience included leadership roles at GlaxoSmithKline, DuPont Pharmaceuticals and DuPont Merck Pharmaceuticals. Dr. Manion received a B.A.Sc degree in Civil Engineering followed by an M.D. degree from the University of Ottawa in Canada. He is Board Certified in Internal Medicine, completed an Infectious Diseases Clinical Fellowship from the University of Ottawa and completed a post-doctoral research fellowship at Massachusetts General Hospital and Harvard Medical School. Dr. Manion serves on the board of directors of the private biopharmaceutical company Lakewood-Amedex, Inc. Our Board believes that Dr. Manion’s extensive leadership experience in clinical and drug development and his knowledge of the pharmaceutical industry, as well as his medical experience, qualifies him to serve as a director of our company.
Neal Walker, age 53
10
Neal Walker co-founded our company and served as Chief Executive Officer from our inception in 2012 until December 2022. Dr. Walker has also served as a member of our Board since our inception and currently serves as its Chair. Dr. Walker co-founded NeXeption, LLC, a biopharmaceutical assets management company, in 2012. Dr. Walker co-founded and served as President and Chief Executive Officer and a member of the board of directors of Vicept Therapeutics, Inc., a dermatology-focused specialty pharmaceutical company, from 2009 until its acquisition by Allergan, Inc. in 2011. Previously, Dr. Walker co-founded and led a number of life science companies, including Octagon Research Solutions, Inc., a software and services provider to biopharmaceutical companies (acquired by Accenture plc), Trigenesis Therapeutics, Inc., a specialty dermatology company, where he served as Chief Medical Officer (acquired by Dr. Reddy’s Laboratories Inc.), and Cutix Inc., a commercial dermatology company. He began his pharmaceutical industry career at Johnson and Johnson, Inc. Dr. Walker is a director of Aldeyra Therapeutics, Inc., a publicly held biotechnology company, as well as several private companies. Dr. Walker received an M.B.A. degree from The Wharton School of the University of Pennsylvania, a Doctor of Osteopathic Medicine degree from the Philadelphia College of Osteopathic Medicine and a B.A. degree in Biology from Lehigh University. Dr. Walker’s experience as a board-certified dermatologist and the founder of our company and other pharmaceutical companies, his background in clinical and drug development in dermatology and other fields, and his knowledge of the pharmaceutical industry contributed to the conclusion of our Board that he should serve as a director of our company.
William Humphries, age 56
William Humphries has served as a member of our Board since 2016. Mr. Humphries joined Isosceles Pharmaceuticals Inc., a biotechnology company, in May 2021 and serves as its Chief Executive Officer. From August 2018 to December 2020, Mr. Humphries served as President of Ortho Dermatologics, the dermatology division of Bausch Health Companies, Inc., and previously served as its Executive Vice President, Company Group Chairman for Dermatology and OraPharma from 2017 to August 2018. From 2012 to 2016, he served as President and Chief Executive Officer of the North American business of Merz, Inc., an affiliate of Merz Pharma Group, a specialty healthcare company. From 2006 to 2012, Mr. Humphries served in a number of leadership positions with Stiefel Laboratories, Inc., a dermatology pharmaceutical company, including as its Chief Commercial Officer and then as President beginning in 2008. Stiefel was acquired by GSK in 2009, after which Mr. Humphries served as the President of Dermatology for Stiefel from 2009 until March 2012. Mr. Humphries previously held multiple senior executive roles in sales and marketing, business development and international marketing for Allergan, Inc., concluding as Vice President of its U.S. skincare business. Mr. Humphries currently serves as chairman of the boards of directors of Clearside Biomedical, Inc., a publicly held biopharmaceutical company, and STRATA Skin Sciences, Inc., a publicly held medical technology company, as a director of the publicly held company PhaseBio Pharmaceuticals, Inc. and as a director of Bryn Pharmaceuticals and SKNV, both privately held life science companies. He received a B.A. degree from Bucknell University and an M.B.A. degree from Pepperdine University. Our Board believes that Mr. Humphries’ experience as a pharmaceutical company executive provides him with the qualifications and skills to serve as a director of our company.
Andrew Schiff, M.D., age 57
Andrew Schiff has served as a member of our Board since 2017. Dr. Schiff joined Aisling Capital, an investment firm, in 1999 and currently serves as one of its managing partners. Prior to joining Aisling Capital, Dr. Schiff practiced internal medicine for six years at The New York Presbyterian Hospital, where he maintains his position as a Clinical Assistant Professor of Medicine. Dr. Schiff currently serves on the board of directors of the publicly held company Monte Rosa Therapeutics, Inc. Dr. Schiff also currently serves on the board of directors of the privately held company Dren Bio. He is a board member of the Visiting Nurse Service of New York, as well as other charitable organizations. Dr. Schiff received an M.D. degree from Cornell University Medical College, an M.B.A. degree from Columbia University, and a B.S. degree with honors in Neuroscience from Brown University. Our Board believes that Dr. Schiff’s medical background and venture capital experience qualify him to serve as a director of our company.
11
BOARD DIVERSITY MATRIX
Board Diversity Matrix (As of April 1, 2023) | ||||
Total Number of Directors |
| 10 | ||
|
| Female |
| Male |
Part I: Gender Identity |
|
|
|
|
Directors |
| 1 |
| 9 |
Part II: Demographic Background |
|
|
|
|
Asian |
| — |
| 1 |
White |
| 1 |
| 8 |
Board Diversity Matrix (As of April 1, 2022) | ||||
Total Number of Directors |
| 9 | ||
|
| Female |
| Male |
Part I: Gender Identity |
|
|
|
|
Directors |
| 1 |
| 8 |
Part II: Demographic Background |
|
|
|
|
Asian |
| — |
| 1 |
White |
| 1 |
| 7 |
INFORMATION REGARDING THE BOARD OF DIRECTORS AND CORPORATE GOVERNANCE
INDEPENDENCE OF THE BOARD OF DIRECTORS
As required under the Nasdaq Stock Market (“Nasdaq”) listing standards, a majority of the members of a listed company’s board of directors must qualify as “independent,” as affirmatively determined by the Board. The Board consults with the Company’s counsel to ensure that the Board’s determinations are consistent with relevant securities and other laws and regulations regarding the definition of “independent,” including those set forth in pertinent listing standards of Nasdaq, as in effect from time to time.
Consistent with these considerations, after review of all relevant identified transactions or relationships between each director, or any of his or her family members, and our company, senior management and independent auditors, the Board has affirmatively determined that eight of our ten current directors are independent directors within the meaning of the applicable Nasdaq listing standards: Mr. Humphries, Dr. Mehra, Mr. Molineaux, Mr. Powell, Mr. Reasons, Dr. Schiff, Dr. Gowen and Mr. Milano. In making these determinations, the Board found that none of these directors had a material or other disqualifying relationship with our company. Dr. Manion, our President and Chief Executive Officer, is not independent as a result of his employment by our company. Dr. Walker, as our prior President and Chief Executive Officer, is not independent as a result of his former employment by our company within the past three years.
BOARD LEADERSHIP STRUCTURE
Dr. Walker was appointed as the chair of our Board effective January 1, 2023, following his resignation as our Chief Executive Officer and the appointment of Dr. Manion as our current Chief Executive Officer. The Chair has authority, among other things, to call and preside over Board meetings, to set meeting agendas and to determine materials to be distributed to the Board and, as a result, has substantial ability to shape the work of the Board. The Company believes that separating the positions of Chair and Chief Executive Officer creates an environment that is more conducive to objective evaluation and oversight of management’s performance, increasing management accountability and improving the ability of the Board to monitor whether management’s actions are in the best interests of the Company and its stockholders. The Company believes that this separation can enhance the effectiveness of the Board as a whole.
Because the Company does not have an independent chair, on January 1, 2023, the Company designated a lead independent director, Mr. Molineaux, who previously served as Chair and is responsible for coordinating the activities of the independent directors. The Board believes that the position of lead independent director helps to reinforce the
12
independence of the Board as a whole. The lead independent director is empowered to, among other duties and responsibilities, preside over Board meetings in the absence of the Chair, preside over and establish the agendas for meetings of the independent directors, act as liaison between the Chair, Chief Executive Officer and the independent directors, provide feedback on the information sent to the Board, preside over any portions of Board meetings at which the evaluation or compensation of the Chief Executive Officer is presented or discussed and, as appropriate upon request, act as a liaison to stockholders. In addition, it is the responsibility of the lead independent director to coordinate between the Board and management with regard to the determination and implementation of responses to any problematic risk management issues. As a result, the Company believes that the lead independent director can help ensure the effective independent functioning of the Board in its oversight responsibilities. In addition, the Company believes that the lead independent director is better positioned to build a consensus among directors and to serve as a conduit between the other independent directors and the Chair, for example, by facilitating the inclusion on meeting agendas of matters of concern to the independent directors.
ROLE OF THE BOARD IN RISK OVERSIGHT
One of the Board’s key functions is informed oversight of the Company’s risk management process. The Board does not have a standing risk management committee, but rather administers this oversight function directly through the Board as a whole, as well as through various Board standing committees that address risks inherent in their respective areas of oversight, including operational, financial, legal and regulatory, cybersecurity, strategic and reputational risks. In particular, our Board is responsible for monitoring and assessing strategic risk exposure, including a determination of the nature and level of risk appropriate for the Company. Our Audit Committee has the responsibility to consider and discuss our major financial risk exposures and the steps our management has taken to monitor and control these exposures, including guidelines and policies to govern the process by which risk assessment and management is undertaken. The Audit Committee also monitors compliance with legal and regulatory requirements, in addition to oversight of the performance of our internal audit function, if and to the extent that we establish such a function. Our Nominating and Corporate Governance Committee monitors the effectiveness of our corporate governance principles, including whether they are successful in preventing illegal or improper liability-creating conduct. Our Nominating and Corporate Governance Committee also periodically reviews and assesses the adequacy of our Corporate Governance Guidelines. Our Compensation Committee assesses and monitors whether any of our compensation policies and programs has the potential to encourage excessive risk-taking. It is the responsibility of the committee chairs to report findings regarding material risk exposures to the Board as quickly as possible. The Lead Independent Director coordinates between the Board and management with regard to the determination and implementation of responses to any problematic risk management issues.
MEETINGS OF THE BOARD OF DIRECTORS
The Board met five times during 2022. Each Board member attended 75% or more of the aggregate number of meetings of the Board and of the committees on which he or she served, held during the portion of 2022 for which he or she was a director or committee member.
As required under applicable Nasdaq listing standards, during 2022 our independent directors met in executive sessions at which only independent directors were present.
INFORMATION REGARDING COMMITTEES OF THE BOARD OF DIRECTORS
The Board has an Audit Committee, a Compensation Committee, a Nominating and Corporate Governance Committee, and a Research and Development Committee. The following table provides membership and meeting information for 2022 for the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee. The Board has determined that each member of the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee meets the applicable Nasdaq rules and regulations regarding “independence” and that each
13
member is free of any relationship that would impair his or her individual exercise of independent judgment with regard to the Company.
|
| |
| |
| Nominating and |
| | | | | | Corporate |
Name | | Audit | | Compensation | | Governance |
William Humphries |
| |
|
|
| X |
Anand Mehra, M.D. |
| |
| X |
|
|
Christopher Molineaux |
| |
|
|
| X* |
Andrew Powell |
| X |
| |
| X |
Bryan Reasons |
| X* |
|
|
|
|
Andrew Schiff, M.D. |
| |
| X |
|
|
Maxine Gowen, Ph.D. |
| X |
| X* |
|
|
Vincent Milano |
| |
| X |
|
|
Total meetings in 2022 |
| 6 |
| 4 |
| 4 |
*Committee Chair
Below is a description of each of the committees of the Board. Each of the committees has authority to engage legal counsel or other experts or consultants, as it deems appropriate to carry out its responsibilities.
Audit Committee
The Audit Committee is currently composed of three directors: Mr. Reasons, Dr. Gowen and Mr. Powell. Mr. Reasons currently serves as the chair of the Audit Committee. The Audit Committee met six times during 2022. The Board has adopted a written Audit Committee charter that is available to stockholders on the Company’s website at www.aclaristx.com.
The Board reviews the Nasdaq listing standards definition of independence for Audit Committee members on an annual basis and has determined that all members of the Company’s Audit Committee are independent (as independence is currently defined in Rule 5605(c)(2)(A)(i) and (ii) of the Nasdaq listing standards and under Rule 10A-3 under the Exchange Act).
The Board has also determined that Mr. Reasons qualifies as an “audit committee financial expert,” as defined in applicable SEC rules. The Board made a qualitative assessment of Mr. Reasons’ level of knowledge and experience based on a number of factors, including his formal education and experience as a chief financial officer for public reporting companies.
The Audit Committee of the Board was established by the Board in accordance with Section 3(a)(58)(A) of the Exchange Act to oversee the Company’s corporate accounting and financial reporting processes and audits of its financial statements. For this purpose, the Audit Committee performs several functions. The Audit Committee evaluates the performance of and assesses the qualifications of the independent auditors; determines and approves the engagement of the independent auditors; determines whether to retain or terminate the existing independent auditors or to appoint and engage new independent auditors; reviews and approves the retention of the independent auditors to perform any proposed permissible non-audit services; monitors the rotation of partners of the independent auditors on the Company’s audit engagement team as required by law; reviews and approves or rejects transactions between the Company and any related persons; confers with management and the independent auditors regarding the effectiveness of internal control over financial reporting; establishes procedures, as required under applicable law, for the receipt, retention and treatment of complaints received by the Company regarding accounting, internal accounting controls or auditing matters and the confidential and anonymous submission by employees of concerns regarding questionable accounting or auditing matters; oversees the Company’s information technology risk exposures, including cybersecurity, data privacy and data security; and meets to review the Company’s annual audited financial statements and quarterly financial statements with management and the independent auditor, including a review of the Company’s disclosures under “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”
14
Report of the Audit Committee of the Board of Directors (1)
The Audit Committee has reviewed and discussed the audited financial statements for the fiscal year ended December 31, 2022 with management of the Company. The Audit Committee has discussed with the independent registered public accounting firm the matters required to be discussed by the applicable requirements of the Public Company Accounting Oversight Board (“PCAOB”) and the SEC. The Audit Committee has also received the written disclosures and the letter from the independent registered public accounting firm required by applicable requirements of the PCAOB regarding the independent accountants’ communications with the Audit Committee concerning independence, and has discussed with the independent registered public accounting firm the accounting firm’s independence. Based on the foregoing, the Audit Committee has recommended to the Board of Directors that the audited financial statements be included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022.
Bryan Reasons, Chair
Maxine Gowen, Ph.D.
Andrew Powell
| (1) | The material in this report is not “soliciting material,” is not deemed “filed” with the SEC and is not to be incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing. |
Compensation Committee
The Compensation Committee is currently composed of four directors: Dr. Gowen, Dr. Mehra, Mr. Milano and Dr. Schiff. Dr. Gowen currently serves as the chair of the Compensation Committee. All members of the Company’s Compensation Committee are independent (as independence is currently defined in Rule 5605(d)(2) of the Nasdaq listing standards). The Compensation Committee met four times during 2022. The Board has adopted a written Compensation Committee charter that is available to stockholders on the Company’s website at www.aclaristx.com.
The Compensation Committee of the Board acts on behalf of the Board to review, adopt and oversee the Company’s compensation strategy, policies, plans and programs, including:
| ● | establishment of corporate objectives relevant to the compensation of the Company’s executive officers and members of senior management and evaluation of performance in light of these stated objectives; |
| ● | review and approval of the compensation and other terms of employment or service, including severance and change-in-control arrangements, of the Company’s Chief Executive Officer and the other executive officers; |
| ● | compensation of the Company’s non-employee directors; |
| ● | reviewing compensation practices and trends to assess the adequacy and competitiveness of the Company’s executive compensation programs among comparable companies in the Company’s industry; and |
| ● | administration of the Company’s equity compensation plans and other similar plans and programs. |
Compensation Committee Processes and Procedures
Typically, the Compensation Committee meets four to five times per year and with greater frequency if necessary. The agenda for each meeting is usually developed by the Chair of the Compensation Committee, in consultation with management. The Compensation Committee meets regularly in executive session. However, from time to time, various members of management and other employees as well as outside advisers or consultants may be invited by the Compensation Committee to make presentations, to provide financial or other background information or advice or to otherwise participate in Compensation Committee meetings. The Chief Executive Officer may not participate in, or be present during, any deliberations or determinations of the Compensation Committee regarding his compensation. The
15
charter of the Compensation Committee grants the Compensation Committee full access to all books, records, facilities and personnel of the Company. In addition, under the charter, the Compensation Committee has the authority to obtain, at the expense of the Company, advice and assistance from compensation consultants and internal and external legal, accounting or other advisers and other external resources that the Compensation Committee considers necessary or appropriate in the performance of its duties. The Compensation Committee has direct responsibility for the oversight of the work of any consultants or advisers engaged for the purpose of advising the Compensation Committee. In particular, the Compensation Committee has the sole authority to retain, in its sole discretion, compensation consultants to assist in its evaluation of executive and director compensation, including the authority to approve the consultant’s reasonable fees and other retention terms. Under the charter, the Compensation Committee may select, or receive advice from, a compensation consultant, legal counsel or other adviser to the Compensation Committee, other than in-house legal counsel and certain other types of advisers, only after taking into consideration six factors, prescribed by the SEC and Nasdaq, that bear upon the adviser’s independence; however, there is no requirement that any adviser be independent.
After taking into consideration the six factors prescribed by the SEC and Nasdaq, the Compensation Committee engaged Pearl Meyer & Partners, LLC (“Pearl Meyer”), a compensation consulting firm, as a compensation consultant in 2021 and 2022. The Compensation Committee assessed Pearl Meyer’s independence and determined that Pearl Meyer had no conflicts of interest in connection with its provision of services to the Compensation Committee. Specifically, the Compensation Committee engaged Pearl Meyer to serve as its independent compensation adviser. Pearl Meyer’s engagement included, but was not limited to, recommending our peer company group for executive and outside director compensation benchmarking, conducting a compensation assessment analyzing the current cash and equity compensation of our executive officers, directors and other senior management against compensation for similarly situated executives and directors at our peer group companies, assisting with the structuring of incentive compensation arrangements, and assisting with the development of competitive compensatory severance provisions to be included in employment or severance agreements. Our management did not have the ability to direct Pearl Meyer’s work.
In accordance with the Company’s 2015 Equity Incentive Plan (the “2015 Plan”) and the authority delegated to the Compensation Committee by the Board, the Compensation Committee has delegated to the Company’s Chief Executive Officer its authority to grant, without any further action required by the Board or the Compensation Committee, stock options and restricted stock units to employees who are not officers of the Company within specified equity award guidelines established by the Compensation Committee. The purpose of this delegation of authority is to enhance the flexibility of equity award administration and to facilitate the timely grant of equity awards to non-management employees.
The Compensation Committee makes most of the significant adjustments to annual compensation, determined bonus and equity awards and established new performance objectives at one or more meetings typically held during the first quarter of the year. The Compensation Committee also considers matters related to individual compensation, such as compensation for new executive hires, as well as high-level strategic issues, such as the efficacy of our compensation strategy, potential modifications to that strategy and new trends, plans or approaches to compensation, at various meetings throughout the year. Generally, the Compensation Committee’s process comprises two related elements: the determination of compensation levels and the establishment of performance objectives for the current year. For executives other than the Chief Executive Officer, the Compensation Committee solicits and considers evaluations and recommendations submitted to the Compensation Committee by the Chief Executive Officer. In the case of the Chief Executive Officer, the evaluation of his performance is conducted by the Compensation Committee, which determines any adjustments to his compensation as well as awards to be granted. For all executives and directors as part of its deliberations, the Compensation Committee may review and consider, as appropriate, materials such as financial reports and projections, operational data, tax and accounting information, tally sheets that set forth the total compensation that may become payable to executives in various hypothetical scenarios, executive and director stock ownership information, stock performance data, analyses of historical executive compensation levels and current Company-wide compensation levels and recommendations of the Compensation Committee’s compensation consultant, including analyses of executive and director compensation paid at other companies suggested by the consultant to be comparable to us.
Compensation Committee Interlocks and Insider Participation
Drs. Gowen, Mehra and Schiff and Mr. Milano served as members of our Compensation Committee during 2022. None of our executive officers served during 2022 as a member of the compensation committee (or other committee serving an
16
equivalent function) or of the board of directors of any entity that had one or more of its executive officers serving as a member of our Board or our Compensation Committee. None of the members of our Compensation Committee has ever been an officer or employee of our company.
Compensation Committee Report (1)
The Compensation Committee has reviewed and discussed with management the Compensation Discussion and Analysis contained in this proxy statement. Based on its review and discussion with management, the Compensation Committee recommended to the Board of Directors that the Compensation Discussion and Analysis be included in this proxy statement and incorporated by reference in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.
Maxine Gowen, Ph.D., Chair
Anand Mehra, M.D.
Vincent Milano
Andrew Schiff, M.D.
| (1) | The material in this report is not “soliciting material,” is not deemed “filed” with the SEC and is not to be incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing. |
Nominating and Corporate Governance Committee
The Nominating and Corporate Governance Committee is currently composed of three directors: Mr. Molineaux, Mr. Humphries and Mr. Powell. Mr. Molineaux currently serves as the chair of the Nominating and Corporate Governance Committee. All members of the Nominating and Corporate Governance Committee are independent (as independence is currently defined in Rule 5605(a)(2) of the Nasdaq listing standards). The Nominating and Corporate Governance Committee met four times during 2022. The Board has adopted a written Nominating and Corporate Governance Committee charter that is available to stockholders on the Company’s website and www.aclaristx.com.
The Nominating and Corporate Governance Committee of the Board is responsible for identifying, reviewing and evaluating candidates to serve as directors of the Company (consistent with criteria approved by the Board), reviewing and evaluating incumbent directors, recommending to the Board for selection candidates for election to the Board, making recommendations to the Board regarding the membership of the committees of the Board, assessing the performance of management and the Board, and developing a set of corporate governance principles for the Company.
The Nominating and Corporate Governance Committee believes that candidates for director should have certain minimum qualifications, including the ability to read and understand basic financial statements, being over 21 years of age, being able to serve for three years before reaching the retirement age of 79 and having the highest personal integrity and ethics. The Nominating and Corporate Governance Committee also intends to consider such factors as possessing relevant expertise upon which to be able to offer advice and guidance to management, having sufficient time to devote to the affairs of the Company, demonstrated excellence in his or her field, having the ability to exercise sound business judgment, diversity and having the commitment to rigorously represent the long-term interests of the Company’s stockholders. However, the Nominating and Corporate Governance Committee retains the right to modify these qualifications from time to time. Candidates for director nominees are reviewed in the context of the current composition of the Board, the operating requirements of the Company and the long-term interests of stockholders. In conducting this assessment, the Nominating and Corporate Governance Committee typically considers diversity, age, skills and such other factors as it deems appropriate, given the current needs of the Board and the Company, to maintain a balance of knowledge, experience and capability. Although the Company does not have a formal policy governing diversity among directors, the Board strives to identify candidates with diverse backgrounds. The Board recognizes the value of overall diversity and considers members’ and candidates’ opinions, perspectives, personal and professional experiences, and backgrounds, including age, gender, race, ethnicity, and country of origin. We believe that the judgment and perspectives offered by a diverse board of directors improves the quality of decision making and enhances our business performance. For additional information regarding the current composition of our Board, see “Election of Directors—Board Diversity Matrix.”
17
In the case of incumbent directors whose terms of office are set to expire, the Nominating and Corporate Governance Committee reviews these directors’ overall service to the Company during their terms, including the number of meetings attended, level of participation, quality of performance and any other relationships and transactions that might impair the directors’ independence. The Nominating and Corporate Governance Committee also takes into account the results of the Board’s self-evaluation, conducted annually on a group and individual basis. The Nominating and Corporate Governance Committee considers suggestions of potential candidates for Board membership made by current Board members and may also engage, if it deems appropriate, a professional search firm. The Nominating and Corporate Governance Committee conducts any appropriate and necessary inquiries into the backgrounds and qualifications of possible candidates after considering the function and needs of the Board and evaluates whether the nominee is independent for Nasdaq purposes, which determination is based upon applicable Nasdaq listing standards, applicable SEC rules and regulations and the advice of counsel, if necessary. The Nominating and Corporate Governance Committee meets to discuss and consider the candidates’ qualifications and then selects a nominee for recommendation to the Board by majority vote.
The Nominating and Corporate Governance Committee will consider director candidates recommended by stockholders. The Nominating and Corporate Governance Committee does not intend to alter the manner in which it evaluates candidates, including the minimum criteria set forth above, based on whether or not the candidate was recommended by a stockholder. Stockholders who wish to recommend individuals for consideration by the Nominating and Corporate Governance Committee to become nominees for election to the Board may do so by delivering a written recommendation to the Nominating and Corporate Governance Committee in care of our Corporate Secretary at 640 Lee Road, Suite 200, Wayne, Pennsylvania 19087. Any such recommendation should be delivered at least 90 days, but not more than 120 days, prior to the anniversary date of the mailing of the Company’s proxy statement for the last Annual Meeting of Stockholders. Submissions must include the full name of the proposed nominee, a description of the proposed nominee’s business experience for at least the previous five years, complete biographical information, a description of the proposed nominee’s qualifications as a director and a representation that the nominating stockholder is a beneficial or record holder of the Company’s stock and has been a holder for at least one year. Any such submission must be accompanied by the written consent of the proposed nominee to be named as a nominee and to serve as a director if elected.
Research and Development Committee
The Research and Development Committee is currently composed of three directors: Dr. Mehra, Dr. Gowen and Dr. Schiff. Dr. Mehra currently serves as the chair of the Research and Development Committee. The Board has adopted a written Research and Development Committee charter that is available to stockholders on the Company’s website at www.aclaristx.com.
The Research and Development Committee is responsible for reviewing the Company’s research and development strategy, reviewing and discussing the quality, direction, effectiveness, and competitiveness of the Company’s research and development programs, providing counsel to management regarding new and emerging research and development trends, advising the Board regarding scientific and research and development matters and reviewing the Company’s pipeline of drug candidates and clinical development performance. In addition, the Research and Development Committee, in conjunction with the Board and the Audit Committee, assists with the oversight of the proper and timely disclosure regarding significant issues or problems with ongoing clinical trials, tests or other studies or analyses.
STOCKHOLDER COMMUNICATIONS WITH THE BOARD OF DIRECTORS
The Company considers its relationships with its stockholders to be a high priority. The Company recognizes that stockholders can have divergent interests and different views on the Company’s practices, objectives and time horizons. To ensure that the Board and management have an opportunity to listen to and understand the varying perspectives of the Company’s stockholders, members of the management team and the Board from time to time engage in dialogues with stockholders. As a result of these discussions, management and the Board have gained useful understanding and insight into the views of the Company’s stockholders and will continue to solicit and engage the Company’s stockholders in the future.
18
The Board has adopted a formal process by which stockholders may communicate with the Board or any of its directors. Stockholders who wish to communicate with the Board may do so by sending written communications addressed to our Corporate Secretary at 640 Lee Road, Suite 200, Wayne, Pennsylvania 19087. Each communication must set forth:
| ● | the name and address of the stockholder on whose behalf the communication is sent; and |
| ● | the number and class of shares of the Company that are owned beneficially by such stockholder as of the date of the communication. |
The Secretary will review each communication. The Secretary will forward such communication to the Board or to any individual director to whom the communication is addressed unless the communication contains advertisements or solicitations or is unduly hostile, threatening or similarly inappropriate, in which case the Secretary shall discard the communication.
CODE OF ETHICS
We have adopted the Aclaris Therapeutics, Inc. Code of Business Conduct and Ethics that applies to all officers, directors and employees. The Code of Business Conduct and Ethics is available on our website at www.aclaristx.com. If we make any substantive amendments to the Code of Business Conduct and Ethics or grant any waiver from a provision of the Code of Business Conduct and Ethics to any executive officer or director, we will promptly disclose the nature of the amendment or waiver on our website.
CORPORATE GOVERNANCE GUIDELINES
We have adopted the Aclaris Therapeutics, Inc. Corporate Governance Guidelines to assure that the Board will have the necessary authority and practices in place to review and evaluate our business operations as needed and to make decisions that are independent of our management. The guidelines are also intended to align the interests of directors and management with those of our stockholders. The Corporate Governance Guidelines set forth the practices the Board intends to follow with respect to board composition and selection, board meetings and involvement of senior management, Chief Executive Officer performance evaluation and succession planning and board committees and compensation. The Corporate Governance Guidelines are available on our website at www.aclaristx.com.
19
Proposal 2
ADVISORY VOTE ON EXECUTIVE COMPENSATION
At the 2021 Annual Meeting of Stockholders, our stockholders indicated their preference that we solicit a non-binding advisory vote on the compensation of our named executive officers, commonly referred to as a “say-on-pay vote,” every year. We are following that preference and are again asking the stockholders this year to approve, on an advisory basis, the compensation of our named executive officers as disclosed in this proxy statement in accordance with SEC rules.
This vote is not intended to address any specific item of compensation, but rather the overall compensation of the Company’s named executive officers and the philosophy, policies and practices described in this proxy statement. The compensation of the Company’s named executive officers subject to the vote is disclosed in the Compensation Discussion and Analysis, the compensation tables and the related narrative disclosures that accompany the compensation tables contained in the “Executive Compensation” section in this proxy statement. As discussed in those disclosures, the Company believes that its compensation policies and decisions are strongly aligned with our stockholders’ interests and consistent with current market practices. Compensation of the Company’s named executive officers is designed to enable the Company to attract and retain talented and experienced executives to lead the Company successfully in a competitive environment.
Accordingly, the Board is asking the stockholders to indicate their support for the compensation of the Company’s named executive officers as described in this proxy statement by casting a non-binding advisory vote “FOR” the following resolution:
“RESOLVED, that the compensation paid to the Company’s named executive officers, as disclosed pursuant to Item 402 of Regulation S-K, including the Compensation Discussion and Analysis, the compensation tables and narrative discussion, is hereby APPROVED.”
Because the vote is advisory, it is not binding on the Board or the Company. Nevertheless, the views expressed by the stockholders, whether through this vote or otherwise, are important to management and the Board and, accordingly, the Board and the Compensation Committee intend to consider the results of this vote in making determinations in the future regarding executive compensation arrangements.
Advisory approval of this proposal requires the vote of the holders of a majority of the shares present or represented by proxy and entitled to vote on the matter at the Annual Meeting. Unless the Board decides to modify the frequency of soliciting say-on-pay votes, the next scheduled say-on-pay vote will be at the 2024 Annual Meeting of Stockholders.
The Board Of Directors Recommends
A Vote In Favor Of Proposal 2.
20
PROPOSAL 3
APPROVAL OF INCREASE IN NUMBER OF AUTHORIZED SHARES OF COMMON STOCK
The Board is requesting stockholder approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the Company’s authorized number of shares of common stock from 100,000,000 shares to 200,000,000 shares.
The additional common stock to be authorized by adoption of the amendment would have rights identical to the currently outstanding common stock of the Company. Adoption of the proposed amendment and issuance of the common stock would not affect the rights of the holders of currently outstanding common stock of the Company, except for effects incidental to increasing the number of shares of the Company’s common stock outstanding, such as dilution of the earnings per share and voting rights of current holders of common stock. If the amendment is adopted, it will become effective upon filing of a Certificate of Amendment of the Company’s Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware.
In addition to the 66,688,647 shares of common stock outstanding on December 31, 2022, the Board has reserved 6,687,894 shares for issuance upon exercise of options and rights and settlement of RSUs granted under the Company’s equity incentive plans.
Although at present the Board has no other plans to issue the additional shares of common stock, it desires to have the shares available to provide additional flexibility to use its capital stock for business and financial purposes in the future. The additional shares may be used for various purposes without further stockholder approval. These purposes may include raising capital; providing equity incentives to employees, officers or directors; establishing strategic relationships with other companies; expanding the Company’s business or product lines through the acquisition of other businesses or products; and other purposes.
The additional shares of common stock that would become available for issuance if the proposal were adopted could also be used by the Board to oppose a hostile takeover attempt or to delay or prevent changes in control or management of our company. For example, without further stockholder approval, the Board could strategically sell shares of common stock in a private transaction to purchasers who would oppose a takeover or favor the current Board. Although this proposal to increase the authorized common stock has been prompted by business and financial considerations and not by the threat of any hostile takeover attempt (nor is the Board currently aware of any such attempts directed at our company), nevertheless, stockholders should be aware that approval of the proposal could facilitate future efforts to deter or prevent changes in control of our company, including transactions in which stockholders might otherwise receive a premium for their shares over then current market prices.
The affirmative vote of the holders of a majority of the outstanding shares of the common stock will be required to approve this amendment to the Company’s Amended and Restated Certificate of Incorporation.
THE BOARD OF DIRECTORS RECOMMENDS
A VOTE IN FAVOR OF PROPOSAL 3.
21
PROPOSAL 4
RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The Audit Committee of the Board has selected PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 and has further directed that management submit the selection of its independent registered public accounting firm for ratification by the stockholders at the Annual Meeting. PricewaterhouseCoopers LLP has audited the Company’s financial statements beginning with the year ended December 31, 2013. Representatives of PricewaterhouseCoopers LLP are expected to be present at the Annual Meeting. They will have an opportunity to make a statement if they so desire and will be available to respond to appropriate questions.
Neither the Company’s amended and restated bylaws nor other governing documents or law require stockholder ratification of the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm. However, the Audit Committee of the Board is submitting the selection of PricewaterhouseCoopers LLP to the stockholders for ratification as a matter of good corporate practice. If the stockholders fail to ratify the selection, the Audit Committee of the Board will reconsider whether or not to retain that firm. Even if the selection is ratified, the Audit Committee of the Board in its discretion may direct the appointment of different independent auditors at any time during the year if they determine that such a change would be in the best interests of the Company and its stockholders.
The affirmative vote of the holders of a majority of the shares present or represented by proxy and entitled to vote on the matter at the Annual Meeting will be required to ratify the selection of PricewaterhouseCoopers LLP.
PRINCIPAL ACCOUNTANT FEES AND SERVICES
The following table represents aggregate fees billed to us for the fiscal years ended December 31, 2022 and 2021 by PricewaterhouseCoopers LLP, our principal accountant.
|
| Fiscal Year Ended December 31, | ||||
|
| 2022 |
| 2021 | ||
Audit Fees | | $ | 757,970 | | $ | 799,900 |
All audit fees were pre-approved by the Audit Committee.
PRE-APPROVAL POLICIES AND PROCEDURES
The Audit Committee has adopted a policy and procedures for the pre-approval of audit and non-audit services rendered by our independent registered public accounting firm, PricewaterhouseCoopers LLP. The policy generally pre-approves specified services in the defined categories of audit services, audit-related services and tax services up to specified amounts. Pre-approval may also be given as part of the Audit Committee’s approval of the scope of the engagement of the independent auditor or on an individual, explicit, case-by-case basis before the independent auditor is engaged to provide each service. The pre-approval of services may be delegated to one or more of the Audit Committee’s members, but the decision must be reported to the full Audit Committee at its next scheduled meeting.
THE BOARD OF DIRECTORS RECOMMENDS
A VOTE IN FAVOR OF PROPOSAL 4.
22
MANAGEMENT
The following table sets forth information concerning our executive officers.
Name |
| Position |
Douglas Manion | | President and Chief Executive Officer |
Kevin Balthaser | | Chief Financial Officer |
Joseph Monahan, Ph.D. | | Chief Scientific Officer |
James Loerop | | Chief Business Officer |
Gail Cawkwell, M.D., Ph.D. | | Chief Medical Officer |
INFORMATION ABOUT OUR EXECUTIVE OFFICERS
The following sets forth certain information with respect to our executive officers who are not also directors. Information with respect to Dr. Manion is set forth above under Proposal 1, Election of Directors.
Kevin Balthaser, age 36
Kevin Balthaser has served as our Chief Financial Officer since January 2023. Mr. Balthaser has served in roles of increasing responsibility at our company since 2017, most recently as Vice President, Finance from January 2022 until his appointment as Chief Financial Officer. Before joining our company, he held positions of increasing responsibility within the accounting and finance department at Lannett Company, Inc., a publicly traded generic pharmaceutical company, where he was also a member of the team responsible for executing capital market transactions and acquisitions. Mr. Balthaser began his career with the accounting firm PricewaterhouseCoopers LLP. Mr. Balthaser is a certified public accountant in Pennsylvania. He received his B.S. degree in finance from Pennsylvania State University and his M.B.A. degree from Villanova University.
Joseph Monahan, Ph.D., age 67
Joseph Monahan, Ph.D., has served as our Chief Scientific Officer since January 2021. From 2017 to January 2021, Dr. Monahan served as our Executive Vice President, Research and Development. In 2010, Dr. Monahan founded a biotechnology company, Confluence Life Sciences, Inc., and functioned as its Chief Scientific Officer until our acquisition of Confluence in 2017. He has also held multiple research leadership positions at Pfizer Inc., including Executive Director, Inflammation Research, global kinase platform leadership team lead; site head of enzymology and biophysics, and inflammation research and development lead. He has held adjunct and visiting professor positions at Washington University Medical School, University of Missouri and University of California, Los Angeles School of Medicine. Dr. Monahan received his B.S. degree in biochemistry from the University of New York at Buffalo and a Ph.D. degree in biochemistry from the University of South Carolina.
James Loerop, age 59
James Loerop has served as our Chief Business Officer since January 2022. From July 2019 to January 2022, Mr. Loerop served as Executive Vice President, Business Development and Strategic Planning at Anika Therapeutics, Inc., a publicly held company focused on products for joint preservation, where he was responsible for global business development activities. From 2017 to July 2019, Mr. Loerop served as Chief Corporate Development Officer for Lupin Pharmaceuticals, Inc., where he was a member of the company’s Executive Leadership Team and was responsible for global business development and corporate development activities. Prior to joining Lupin, Mr. Loerop held senior leadership roles at various companies in the pharmaceutical and life sciences industry, including at Alexion Pharmaceuticals, Inc. as Senior Vice President of Global Business Development, GlaxoSmithKline as Vice President of North America Business Development, and Stiefel Laboratories, Inc. as Senior Vice President of Global Corporate Development, prior to GSK’s acquisition of Stiefel. Mr. Loerop received a B.S. degree in marketing from Western Michigan University.
23
Gail Cawkwell, M.D., Ph.D., age 61
Gail Cawkwell, M.D., Ph.D. has served as our Chief Medical Officer since June 2022. Dr. Cawkwell served as Senior Vice President, Medical Affairs, Safety & Pharmacovigilance at Intercept Pharmaceuticals, Inc. from September 2018 to June 2022 and as Senior Vice President, Medical Affairs from 2018 to September 2018. From 2015 to 2018, Dr. Cawkwell worked for Purdue Pharma L.P. in multiple roles, including as Special Advisor to the Board of Directors, Chief Medical Officer and Vice President, Medical Affairs. From 2000 to 2014, Dr. Cawkwell served in a number of roles of increasing responsibility at Pfizer Inc., including most recently as Vice President Medicine Team Lead for Pfizer's tofacitinib franchise. Dr. Cawkwell also served as a Clinical Instructor of Pediatrics at Columbia Presbyterian Health Center from 2002 to 2015 and previously held several other clinical and academic posts. Dr. Cawkwell received a Ph.D. in epidemiology from the University of Cincinnati, a M.D. from McGill University in Montreal, Canada, and a B.S. degree from Duke University.
24
SECURITY OWNERSHIP OF
CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following table sets forth certain information regarding the ownership of our common stock as of April 4, 2023 by: (i) each director; (ii) each of the executive officers listed in the Summary Compensation Table; (iii) all currently serving executive officers and directors as a group; and (iv) all those known by us to be beneficial owners of more than five percent of our common stock.
|
| Number of |
| Percent of |
| ||||||||
| | Shares | | Shares |
| ||||||||
| | Beneficially | | Beneficially |
| ||||||||
Beneficial Owner(1) |
| Owned |
| Owned | | ||||||||
5% Stockholders: |
|
|
|
| | ||||||||
Entities affiliated with Wellington Management Group LLP(2) |
| 7,372,601 |
| 10.4 | % | ||||||||
Entities affiliated with Blackrock, Inc.(3) |
| 5,087,435 |
| 7.2 | | ||||||||
Entities affiliated with Venrock Healthcare Capital Partners II, L.P.(4) |
| 4,563,962 |
| 6.5 | | ||||||||
Entities affiliated with RA Capital Management, L.P.(5) |
| 4,398,453 |
| 6.2 | | ||||||||
Entities affiliated with Foresite Capital Fund IV, L.P.(6) |
| 4,066,277 |
| 5.8 | | ||||||||
Rock Springs Capital Management LP(7) |
| 3,961,249 |
| 5.6 | | ||||||||
| | | | | | ||||||||
Named Executive Officers and Directors: |
|
|
|
| | ||||||||
Neal Walker(8) |
| 2,484,333 |
| 3.5 | | ||||||||
Frank Ruffo(9) |
| 644,578 |
| * | | ||||||||
Joseph Monahan(10) |
| 256,892 |
| * | | ||||||||
Douglas Manion(11) | | 12,800 | | * | | ||||||||
Gail Cawkwell | | — | | — | | ||||||||
William Humphries(12) |
| 94,572 |
| * | | ||||||||
Christopher Molineaux(13) |
| 109,279 |
| * | | ||||||||
Anand Mehra(14) |
| 91,204 |
| * | | ||||||||
Andrew Powell(15) |
| 90,863 |
| * | | ||||||||
Bryan Reasons(16) |
| 84,572 |
| * | | ||||||||
Andrew Schiff(17) |
| 507,462 |
| * | | ||||||||
Maxine Gowen(18) |
| 72,801 |
| * | | ||||||||
Vincent Milano(19) |
| 74,363 |
| * | | ||||||||
All current directors and executive officers as a group (14 persons)(20) |
| 3,959,530 |
| 5.5 | | ||||||||
* | Less than one percent. |
| (1) | This table is based upon information supplied by officers, directors and principal stockholders and a review of Schedule 13G and Schedule 13D and Section 16 filings with the SEC. Unless otherwise indicated in the footnotes to this table and subject to community property laws where applicable, we believe that each of the stockholders named in this table has sole voting and investment power with respect to the shares indicated as beneficially owned. Applicable percentages are based on 70,679,395 shares outstanding on April 4, 2023, adjusted as required by rules promulgated by the SEC. Except as otherwise noted below, the principal business address of each of the executive officers and directors is c/o Aclaris Therapeutics, Inc., 640 Lee Road, Suite 200, Wayne, Pennsylvania 19087. |
| (2) | This information has been obtained from a Schedule 13G/A filed on April 10, 2023 by Wellington Management Group LLP, Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP and Wellington Management Company LLP. The principal business address of these entities is c/o Wellington Management Company LLP, 280 Congress Street, Boston, MA 02210. |
| (3) | This information has been obtained from a Schedule 13G/A filed on January 31, 2023 by Blackrock, Inc. The principal business address of BlackRock, Inc. is 55 East 52nd Street, New York, NY 10055. |
25
| (4) | This information has been obtained from a Schedule 13G filed on February 14, 2022 by Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh. VHCP Management II, LLC is the general partner of Venrock Healthcare Capital Partners II, L.P. and the manager of VHCP Co-Investment Holdings II, LLC, VHCP Management III, LLC is the general partner of Venrock Healthcare Capital Partners III, L.P. and the manager of VHCP Co-Investment Holdings III, LLC, VHCP Management EG, LLC is the general partner of Venrock Healthcare Capital Partners EG, L.P., and Messrs. Shah and Koh are the voting members of VHCP Management II, LLC, VHCP Management III, LLC and VHCP Management EG, LLC. The principal business address of these entities and persons is 7 Bryant Park, 23rd Floor, New York, NY 10018. |
| (5) | This information has been obtained from a Schedule 13G filed on April 25, 2022 by RA Capital Management, L.P, Peter Kolchinsky, Rajeev Shah and RA Capital Healthcare Fund, L.P. RA Capital Healthcare Fund GP, LLC is the general partner of RA Capital Healthcare Fund, L.P. The general partner of RA Capital Management, L.P. is RA Capital Management GP, LLC of which Dr. Kolchinsky and Mr. Shah are the controlling persons. RA Capital Management, L.P. serves as investment advisor for RA Capital Healthcare Fund, L.P. The principal business address of these entities and persons is c/o RA Capital Management, L.P., 200 Berkeley Street, 18th Floor, Boston, MA 02116. |
| (6) | This information has been obtained from a Schedule 13G/A filed on February 13, 2023 by Foresite Capital Fund IV, L.P., Foresite Capital Management IV, LLC, Foresite Capital Fund V, L.P., Foresite Capital Management V, LLC and James Tananbaum. Foresite Capital Management IV, LLC is the General Partner of Foresite Capital Fund IV, L.P.; Foresite Capital Management V, LLC is the General Partner of Foresite Capital Fund V, L.P.; James Tananbaum is the managing member of each of Foresite Capital Management IV, LLC and Foresite Capital Management V, LLC. The principal business address of these entities and person is c/o Foresite Capital Management, 900 Larkspur Landing Circle, Suite 150, Larkspur, CA 94939. |
| (7) | This information has been obtained from a Schedule 13G/A filed on February 14, 2023 by Rock Springs Capital Management LP, Rock Springs Capital LLC, its general partner, and Rock Springs Capital Master Fund LP, which states that the shares are held directly by Rock Springs Capital Master Fund LP and Four Pines Master Fund LP. Rock Springs Capital Management LP serves as the investment manager to each of Rock Springs Capital Master Fund LP and Four Pines Master Fund LP. The principal business address of Rock Springs Capital Management LP is 650 South Exeter St., Suite 1070, Baltimore, MD 21202. |
| (8) | Consists of (a) 1,273,202 shares of common stock and (b) 1,211,131 shares of common stock underlying options that are exercisable within 60 days of April 4, 2023. |
| (9) | Consists of (a) 201,833 shares of common stock and (b) 442,695 shares of common stock underlying options that are exercisable within 60 days of April 4, 2023. |
| (10) | Consists of (a) 147,724 shares of common stock owned directly by Dr. Monahan, (b) 193 shares of common stock owned directly by his spouse and (c) 108,975 shares of common stock underlying options that are exercisable within 60 days of April 4, 2023. |
| (11) | Consists of 12,800 shares of common stock. |
| (12) | Consists of (a) 19,565 shares of common stock, (b) 70,500 shares of common stock underlying options that are exercisable within 60 days of April 4, 2023 and (c) 4,507 shares of common stock underlying restricted stock units that will vest within 60 days of April 4, 2023. |
| (13) | Consists of (a) 27,247 shares of common stock, (b) 77,525 shares of common stock underlying options that are exercisable within 60 days of April 4, 2023 and (c) 4,507 shares of common stock underlying restricted stock units that will vest within 60 days of April 4, 2023. |
26
| (14) | Consists of (a) 34,197 shares of common stock, (b) 52,500 shares of common stock underlying options that are exercisable within 60 days of April 4, 2023 and (c) 4,507 shares of common stock underlying restricted stock units that will vest within 60 days of April 4, 2023. |
| (15) | Consists of (a) 9,856 shares of common stock, (b) 76,500 shares of common stock underlying options that are exercisable within 60 days of April 4, 2023 and (c) 4,507 shares of common stock underlying restricted stock units that will vest within 60 days of April 4, 2023. |
| (16) | Consists of (a) 19,565 shares of common stock, (b) 60,500 shares of common stock underlying options that are exercisable within 60 days of April 4, 2023 and (c) 4,507 shares of common stock underlying restricted stock units that will vest within 60 days of April 4, 2023. |
| (17) | Consists of (a) 434,455 shares of common stock owned directly by Aisling Capital IV, LP (“Aisling”), (b) 68,500 shares of common stock underlying options held directly by Dr. Schiff that are exercisable within 60 days of April 4, 2023 and (c) 4,507 shares of common stock underlying restricted stock units held directly by Dr. Schiff that will vest within 60 days of April 4, 2023. The shares owned directly by Aisling are held indirectly by Aisling Capital Partners IV, LP (“Aisling GP”), as general partner of Aisling, Aisling Capital Partners IV, LLC (“Aisling Partners”), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the “Managers”) of Aisling Partners are Dr. Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. |
| (18) | Consists of (a) 7,794 shares of common stock, (b) 60,500 shares of common stock underlying options that are exercisable within 60 days of April 4, 2023 and (c) 4,507 shares of common stock underlying restricted stock units that will vest within 60 days of April 4, 2023. |
| (19) | Consists of (a) 3,356 shares of common stock, (b) 66,500 shares of common stock underlying options that are exercisable within 60 days of April 4, 2023 and (c) 4,507 shares of common stock underlying restricted stock units that will vest within 60 days of April 4, 2023. |
| (20) | Consists of (a) 2,002,193 shares of common stock, (b) 1,921,281 shares of common stock underlying options that are exercisable within 60 days of April 4, 2023 and (c) 36,056 shares of common stock underlying restricted stock units that will vest within 60 days of April 4, 2023. |
27
EXECUTIVE COMPENSATION
COMPENSATION DISCUSSION AND ANALYSIS
Introduction
This Compensation Discussion and Analysis section of our proxy statement provides our stockholders with an explanation of our compensation philosophy, program, processes, decisions, and other relevant information related to our named executive officers (“NEOs”). Our NEOs for the year ended December 31, 2022 were:
Name | | Position |
Neal Walker | | Former Chief Executive Officer(1) |
Frank Ruffo | | Former Chief Financial Officer(2) |
Joseph Monahan | | Chief Scientific Officer |
Douglas Manion | | President and Chief Operating Officer (3) |
Gail Cawkwell | | Chief Medical Officer(4) |
| (1) | Dr. Walker resigned as Chief Executive Officer effective at the close of business on December 31, 2022 and was appointed as the Chair of the Board effective January 1, 2023. |
| (2) | Mr. Ruffo retired effective at the close of business on December 31, 2022. Kevin Balthaser, previously our Vice President, Finance, began serving as our Chief Financial Officer and an executive officer on January 1, 2023. |
| (3) | Dr. Manion joined our company as President and Chief Operating Officer effective August 1, 2022. In November 2022, he was appointed as our Chief Executive Officer effective January 1, 2023. |
| (4) | Dr. Cawkwell joined our company as Chief Medical Officer effective June 27, 2022. |
Executive Summary
Our 2022 Business Performance
We accomplished several important goals in 2022 that relate to our overall corporate mission and strategy of developing novel drug candidates for immuno-inflammatory diseases:
| ● | Completed enrollment in a Phase 2a trial of zunsemetinib in subjects with moderate to severe hidradenitis suppurativa; |
| ● | Initiated a Phase 2b trial of ATI-1777 in subjects with moderate to severe atopic dermatitis; |
| ● | Successfully completed a Phase 1 single ascending dose (SAD) trial of ATI-2138, an investigational oral covalent ITK/JAK3 inhibitor, and initiated a Phase 1 multiple ascending dose (MAD) trial of ATI-2138; |
| ● | Raised net proceeds of $73 million from sales of our common stock; and |
| ● | Entered into two out-licensing agreements. |
2022 Say on Pay Vote
At the 2022 annual meeting of stockholders, our stockholders approved the compensation of our NEOs on an advisory basis, with approximately 98% of the votes cast “For” such approval. The Compensation Committee interpreted stockholder approval of the executive compensation program at such a level as indicating that a substantial majority of
28
stockholders view our executive compensation program, plan design and governance as continuing to be well aligned with our stockholders, their investor experience and our business outcomes.
Key Compensation Decisions and Actions
Our Compensation Committee took the following actions related to 2022 NEO compensation:
Compensation Area |
| Highlights |
Cash Compensation | | ● Set base salary and target bonus levels for Dr. Manion and Dr. Cawkwell as part of their new hire arrangements ● Approved merit-based base salary increases for Dr. Walker and Mr. Ruffo, as well as a promotional / market adjustment to base salary for Dr. Monahan ● Approved target bonus levels for Dr. Walker, Mr. Ruffo, and Dr. Monahan ● Approved the 2022 corporate incentive goals and weightings and associated NEO target bonuses ● Paid bonuses to our NEOs at a level that reflected performance against our 2022 goals, other significant accomplishments, and individual contributions where applicable |
Equity Compensation | | ● Granted Dr. Walker, Mr. Ruffo, and Dr. Monahan annual long-term incentive grants with 4-year vesting to promote retention and shareholder alignment ● Granted new-hire long-term incentive awards to Dr. Manion and Dr. Cawkwell to aid in attracting them to our company, as well as to promote retention and shareholder alignment ● All equity grants were comprised 70% in stock options and 30% in restricted stock units (“RSUs”) |
Employment Agreements | | ● Entered into amended employment agreements with Dr. Walker and Mr. Ruffo, and entered into new employment agreements with the other NEOs |
Process / Governance | | ● Updated our peer group of comparable companies ● Re-engaged Pearl Meyer as the Compensation Committee’s independent consultant |
29
Key Compensation Governance Attributes
Our Compensation Committee believes that a sound compensation program is grounded in key governance practices and processes that align with our compensation philosophy and objectives. A summary of these key features includes:
What We Do |
| What We Don’t Do |
✓ Utilize “double-trigger” vesting on equity awards ✓ Have a maximum individual payout on our bonus plan ✓ Have an independent Compensation Committee ✓ Consult an independent compensation consultant ✓ Provide a majority of compensation through long-term incentives that have multi-year vesting schedules ✓ Provide a competitive mix of fixed (e.g., base salary) and variable (e.g., bonus) short-term compensation ✓ Evaluate the risk profile of our pay program ✓ Use a consistent approach to granting and pricing equity awards | | ✘ No guaranteed salary increases ✘ No executive-only perquisites ✘ No pension plans ✘ No post-employment benefit plans ✘ No hedging or pledging of Company stock ✘ No history of repricing stock options |
Approach to Compensation
Compensation Philosophy
Our executive compensation program is based on supporting our overall mission to develop novel, small molecule therapies to help patients with immuno-inflammatory diseases for which satisfactory treatment options are not available. We emphasize the following values for our employees:
A commitment to advancing innovation | A patient-centric sense of purpose | A high level of professional integrity |
Our compensation program is designed to attract, retain and motivate our NEOs by:
| ✓ | providing competitive compensation opportunities; |
| ✓ | structuring appropriate levels of risk and reward in proportion to individual contribution and performance; and |
| ✓ | establishing appropriate incentives to further our long-term strategic plan. |
We accomplish these goals through a total view of compensation that covers multiple compensation elements including but not limited to base salary, cash- and equity-based incentives, and health and welfare benefits.
In setting NEO compensation, we consider compensation for comparable positions in the market, the historical compensation levels of our executives, individual performance as compared to our expectations and objectives, our desire to motivate our employees to achieve short- and long-term results that are in the best interests of our stockholders and a long-term commitment to our company. We do not target a specific competitive position or a specific mix of compensation
30
among base salary, bonus or long-term incentives; however, we do deliver a majority of compensation through long-term incentives.
Process and Roles
We review compensation annually for our NEOs, and in some cases more frequently as deemed appropriate. The various roles that contribute to our decisions and actions each year are as follows:
The Compensation Committee. The Compensation Committee is responsible for establishing and overseeing our executive compensation program. Specific responsibilities of the Compensation Committee are described in this proxy statement under “Information Regarding Committees of the Board of Directors—Compensation Committee.” Our Compensation Committee typically reviews and discusses management’s proposed compensation with the Chief Executive Officer for all executives other than the Chief Executive Officer. Based on those discussions and its discretion, the Compensation Committee then recommends the compensation for each NEO. Our Compensation Committee, without members of management present, discusses and ultimately approves the compensation of our executive officers.
Role of our Chief Executive Officer and other Management Members. Our Chief Executive Officer evaluates and reviews with the Compensation Committee the individual performance and contributions of each of the other NEOs and makes recommendations to the Compensation Committee regarding base salary, and short- and long-term incentive awards. The Compensation Committee reviews and considers such recommendations, but ultimately retains full discretion and authority over the final compensation decisions for the NEOs. Our Chief Executive Officer also recommends the Company performance objectives that are used to determine bonus amounts and consults with select members of management in the development of the goals. The Compensation Committee may request that certain executives attend portions of Compensation Committee meetings based on the topics being covered and their respective areas of expertise. NEO compensation decisions are made in executive session without the respective NEOs present.
Role of our Independent Compensation Consultant. The Compensation Committee continues to retain Pearl Meyer, a compensation consulting firm, to evaluate and make recommendations with respect to our executive compensation program. Pearl Meyer’s role included assisting the Compensation Committee with the selection of a peer group of companies for comparison purposes, an analysis of our existing executive compensation, the design of our long-term incentive program, an analysis of our director compensation policy, sharing new developments in areas that fall within the Compensation Committee’s jurisdiction, and advising the Compensation Committee regarding all of its responsibilities. The consultant serves at the pleasure of the Compensation Committee, and the consultant’s fees are approved by the Compensation Committee.
Use of Market Data
The Compensation Committee makes use of market data in making its decisions. One of these references is compensation market data derived from other comparable public companies. In October 2021, Pearl Meyer developed a peer group for use in evaluating the competitiveness of NEO compensation arrangements. The group consisted of 23 companies that were comparable to ours at that time. The key criteria used to arrive at the selected companies was as follows:
| ● | U.S. publicly traded biotechnology or pharmaceutical companies; |
| ● | development-stage; and |
| ● | comparable size, as defined by market capitalization, operating expenses, and number of full-time employees. |
31
In October 2021, the Compensation Committee approved the following peer group, which such group was used by the Compensation Committee in connection with making compensation decisions for 2022:
Aldeyra Therapeutics, Inc. | Forma Therapeutics Holdings, Inc. | RAPT Therapeutics, Inc. |
AlloVir, Inc. | Inhibrx, Inc. | Replimune Group, Inc. |
AnaptysBio, Inc. | iTeos Therapeutics, Inc. | Scholar Rock Holding Corporation |
BioXcel Therapeutics, Inc. | IVERIC bio, Inc. | Selecta Biosciences, Inc. |
C4 Therapeutics, Inc. | Krystal Biotech, Inc. | Seres Therapeutics, Inc. |
Celldex Therapeutics, Inc. | Marinus Pharmaceuticals, Inc. | Spero Therapeutics, Inc. |
Cortexyme, Inc. | Nurix Therapeutics, Inc. | Stoke Therapeutics, Inc. |
Evelo Biosciences, Inc. | Passage Bio, Inc. | |
In September 2022, Pearl Meyer again reviewed the peer group of companies for continued appropriateness. The criteria used to develop this peer group was the same as the previous year, as adjusted for our new organizational size and market capitalization. This criterion resulted in the following peer group of 24 companies used to make compensation decisions for 2023:
Aldeyra Therapeutics, Inc. | Design Therapeutics, Inc. | Replimune Group, Inc. |
AlloVir, Inc. | Evelo Biosciences, Inc. | Scholar Rock Holding Corporation |
AnaptysBio, Inc. | Inhibrx, Inc. | Selecta Biosciences, Inc. |
BioXcel Therapeutics, Inc. | iTeos Therapeutics, Inc. | Seres Therapeutics, Inc. |
C4 Therapeutics, Inc. | IVERIC bio, Inc. | Stoke Therapeutics, Inc. |
Celldex Therapeutics, Inc. | Kymera Therapeutics, Inc. | Syndax Pharmaceuticals, Inc. |
Chinook Therapeutics, Inc. | Nurix Therapeutics, Inc. | Vaxcyte, Inc. |
Day One Biopharmaceuticals, Inc. | RAPT Therapeutics, Inc. | Ventyx Biosciences, Inc. |
From time to time, the Compensation Committee also will make use of industry and size specific survey data to benchmark compensation levels or program practices. Typically, this survey data is used when the peer group disclosures do not contain the type of information being researched or have inadequate sample sizes for benchmarking purposes.
Other Information Used in Decision-Making Process
As part of its deliberations, the Compensation Committee reviews and considers, as appropriate, materials such as financial reports and budgets, tax and accounting information, executive stock ownership information, stock performance data, analyses of historical executive compensation levels and current Company-wide compensation levels and recommendations of the Compensation Committee’s compensation consultant.
Compensation Programs and Decisions
Overview
Compensation for our NEOs is comprised primarily of the following four main components:
| ||
Element | | Summary Purpose |
Base Salary | | Provide a fixed source of income commensurate with the NEOs’ positions at the Company |
Annual Cash Incentive Bonus | | Motivate NEOs to achieve our annual corporate objectives that we believe will translate to long-term stockholder value creation and achievement of our mission |
Long-term Equity Incentives | | Aid in attraction and retention of NEOs and create stockholder alignment |
Benefits | | Provide our NEOs with health and welfare benefits, as well as certain protections if we experience a change of control or an NEO separates |
Each of these key elements is further described below, along with the key decisions made for the 2022 plan year.
32
Annual Base Salary
Base salaries are determined by the Compensation Committee for each NEO. The Compensation Committee considers each NEO’s experience, expertise and performance, market compensation levels for similar positions, recommendations from the Chief Executive Officer (for all NEOs except himself), and recommendations from Pearl Meyer in making decisions regarding salary levels.
The following table presents the annual base salaries for each of our NEOs for 2021 and 2022:
|
| Annual Base Salary |
| |
| | ||
| | ($) | | Percentage | | | ||
Name | | 2021 |
| 2022 | | Increase | | Rationale for Increase |
Neal Walker | | 566,500 | | 589,680 |
| 4.1 | % | Merit Increase |
Frank Ruffo | | 401,700 |
| 417,768 |
| 4.0 | % | Merit Increase |
Joseph Monahan | | 350,000 |
| 420,000 |
| 20.0 | % | Promotion/Market Adjustment(1) |
Douglas Manion | | — |
| 490,000 |
| — | % | Hired in 2022 |
Gail Cawkwell | | — |
| 480,000 |
| — | % | Hired in 2022 |
| (1) | Dr. Monahan was promoted to Chief Scientific Officer in January 2021. The increase shown in the table above was the second of a two-year step-up in base salary intended to align Dr. Monahan with the base salaries of chief scientific officers among the peer group of companies. |
Annual Bonus (Non-Equity Incentive Plan Compensation)
We seek to motivate and reward our executives for achievements relative to our corporate goals and expectations, and with respect to our NEOs other than the Chief Executive Officer, their respective individual goals, for each fiscal year.
The actual annual bonus paid, if any, is calculated by multiplying the NEO’s annual base salary, target bonus percentage, the percentage attainment of the corporate goals established by the Board for such year, and for our NEOs other than the Chief Executive Officer, the percentage attainment of the individual goals established by our Chief Executive Officer. The Compensation Committee is not required to determine bonuses based on this exact formula and reserves the right to consider other factors and adjust bonus amounts accordingly.
For 2022, the bonus funding factor was weighted 75% for corporate goals and 25% for individual goals for all NEOs other than our Chief Executive Officer, whose bonus funding was 100% dependent on the achievement of corporate goals.
After the end of the year, the Compensation Committee reviews our performance against our goals and approves the extent to which we achieved each of our corporate goals and, with the input of our Chief Executive Officer, individual performance, as applicable, and, for each NEO, the amount of the bonus awarded.
The following chart depicts the structure of our annual bonus program for 2022:
Base Salary | X | Target Bonus | X | Bonus Funding Factor | = | Annual Cash | |
Corporate | Individual | ||||||
33
Our Compensation Committee established the following target bonus opportunities for each NEO for 2022 that reflected the individual’s role and also took into consideration target bonuses among executives at peer companies:
|
| |
| |
| 2022 Target |
| | | | 2022 Target Bonus | | Bonus |
| | 2022 Annual Base Salary | | Opportunity (% of Base | | Opportunity |
Name | | ($) | | Salary) | | ($) |
Neal Walker |
| 589,680 |
| 60 | % | 353,808 |
Frank Ruffo |
| 417,768 |
| 40 | % | 167,107 |
Joseph Monahan |
| 420,000 |
| 40 | % | 168,000 |
Douglas Manion |
| 490,000 |
| 40 | % | 82,159(1) |
Gail Cawkwell |
| 480,000 |
| 40 | % | 98,893(1) |
| (1) | These amounts are pro-rated to reflect actual service time in 2022 for the newly hired officers. |
In early 2022, our Compensation Committee approved our 2022 corporate performance goals (which comprise the corporate funding factor used to calculate the bonus funding factor). These goals were divided into two primary categories that the Compensation Committee believed were critical to achieving the Company’s mission: (a) research and development goals, which together comprised 85% of the overall corporate performance target score, and (b) other corporate goals, which comprised 15% of the overall corporate performance target score. These two categories of objectives included specific deliverables, described below, with differing weightings. The Compensation Committee also approved stretch performance goals in both the research and development and other corporate categories that, if earned, could increase the overall funding of the bonus plan up to a maximum of 140% of the corporate performance target score. The plan goals were generally intended to be measured over one year but could be accomplished at various times during the year. For each corporate goal described below, partial credit could be given by the Compensation Committee based on the actual level of achievement. We established goals designed to drive corporate performance that we believed were challenging but also achievable.
In early 2023, the Compensation Committee evaluated the level of achievement for the 2022 corporate performance goals. The following chart provides a summary of the corporate goals for 2022 and resulting assessment of achievement:
|
| |
| Credit Given |
| | | | for |
| | Weighting | | Achievement |
| | (%) | | (%) |
Research and Development |
| 85 |
| 65 |
• Clinical development |
|
|
|
|
• Pre-clinical development |
|
|
|
|
• Discovery and contract research |
|
|
|
|
Other Corporate |
| 15 |
| 15 |
• Business development, financing, investor relations, operational and compliance |
|
|
|
|
Total Score |
| 100 |
| 80 |
Stretch Goals |
| 40 |
| 20 |
• Research and development |
| 35 |
| 15 |
• Other corporate |
| 5 |
| 5 |
Total Score (with Stretch Goals) |
| 140 |
| 100 |
Our research and development goals included various clinical development milestones, including advancing zunsemetinib through a Phase 2b clinical trial in subjects with moderate to severe rheumatoid arthritis, a Phase 2a clinical trial in subjects with moderate to severe psoriatic arthritis, and a Phase 2a clinical trial in subjects with moderate to severe hidradenitis suppurativa, initiating and advancing ATI-1777 through a Phase 2b clinical trial in subjects with moderate to severe atopic dermatitis, and initiating and advancing ATI-2138 through a Phase 1 single ascending dose (“SAD”) study and Phase 1 multiple ascending dose (“MAD”) study; various preclinical development goals including progressing ATI-2231 toward IND submission and advancing our gut-biased program; and various discovery and contract research organization (“CRO”) targets including advancing discovery activities with respect to our pipeline and strengthening our CRO business. The
34
clinical development objectives comprised the largest weighting within this category. The research and development stretch objectives related to more advanced development or additional development of our clinical, pre-clinical and discovery programs and additional goals related to our contract research business.
In assessing our overall level of achievement, the Compensation Committee considered, among other things, the progression of the three Phase 2 trials of zunsemetinib, including the completion of enrollment of the Phase 2a trial in hidradenitis suppurativa, the progression of the Phase 2b trial of ATI-1777, the completion of the Phase 1 SAD trial of ATI-2138 and the initiation of the Phase 1 MAD trial of ATI-2138, the completion of IND-enabling studies for ATI-2231, manufacturing developments, the progression of our discovery pipeline and the improvements with respect to our contract research business. The Compensation Committee concluded that partial credit for our research and development goals was warranted, noting that we had not achieved certain clinical development objectives that could have resulted in full credit. With respect to the stretch goals, the Compensation Committee considered the progress of the strategic plan with respect to ATI-2231, drug discovery improvements, and the results of our contract research business. The Compensation Committee determined that partial credit for the stretch goals was warranted, but full credit was not awarded as we had not achieved some of the development goals.
Our other corporate goals were focused in the areas of business development, financing and investor relations, as well as certain operational and compliance goals. The other corporate stretch goals related to additional business development and operational goals. In assessing our level of achievement of these goals, the Compensation Committee considered, among other things, our net proceeds of $73 million from sales of our common stock, two out-licensing agreements, and the overall expansion of our organization including within senior leadership.
In addition to the corporate performance goals described above, Dr. Walker, who was serving as our Chief Executive Officer in 2022, evaluated the individual performance of each of Mr. Ruffo and Dr. Manion, and together with Dr. Manion evaluated the individual performance of each of Dr. Monahan and Dr. Cawkwell, and recommended a level of achievement to the Compensation Committee. The individual goals focused on contributions toward our corporate objectives as well as the personal qualities necessary to effectively manage a team, solve problems and drive our business forward. Dr. Walker and Dr. Manion, as applicable, recommended full credit for these individual objectives, which the Compensation Committee approved.
Applying the corporate and individual funding factor weightings, the Compensation Committee approved the following bonus payouts for 2022:
|
| |
| |
| |
| |
| Actual |
| | | | Corporate | | Individual | | | | Bonus as a |
| | Target Bonus | | Funding Factor | | Funding Factor | | | | Percent of |
| | Opportunity | | Credit | | Credit | | Earned Bonus | | Target |
Name | | ($) | | (%) | | (%) | | ($) |
| (%) |
Neal Walker |
| 353,808 |
| 100 |
| — |
| 353,808 |
| 100.0 |
Frank Ruffo |
| 167,107 |
| 75* |
| 25 |
| 167,107 |
| 100.0 |
Joseph Monahan |
| 168,000 |
| 75* |
| 25 |
| 168,000 |
| 100.0 |
Douglas Manion | | 82,159 | | 75* | | 25 | | 82,159 | | 100.0 |
Gail Cawkwell | | 98,893 | | 75* | | 25 | | 98,893 | | 100.0 |
* Represents 100% multiplied by 75%, the corporate funding factor for the officer.
Long-term Incentives
Long-term incentives represent a key element of our overall compensation program. This compensation element is primarily used to aid in attracting and retaining the talent we need to achieve our mission, strategies, and underlying corporate goals. Additionally, long-term incentives align the interests of our NEOs with our stockholders.
The Compensation Committee typically approves long-term incentive grants for NEOs at the start of their employment, and annually thereafter in connection with the annual performance review. Additionally, the Compensation Committee
35
may periodically grant additional equity awards based on changes in job responsibility, performance and contribution, or other special circumstances.
For the 2022 plan year, the Compensation Committee approved both stock options and RSUs for NEOs as part of their annual long-term incentive awards, except for Dr. Manion and Dr. Cawkwell, for whom these awards were part of their new hire compensation arrangement and were granted at the start of their employment. The vesting schedules for grants made in 2022 are as follows:
| ● | Stock option grants vest in equal installments on the anniversary of the grant date over a 4-year period |
| ● | RSU grants vest in equal installments on the anniversary of the grant date over a 4-year period |
In determining annual long-term incentive grants for NEOs, the Compensation Committee reviews market data for annual long-term incentive grant levels and groups the NEOs accordingly. The market data that the Compensation Committee reviewed for the purpose of sizing equity grants included long-term incentive awards expressed as a percentage of shares of common stock outstanding, as well as grant date fair values.
In February 2022, the Compensation Committee approved the grant of stock options and RSUs to each of our NEOs who were employed with us at that time. Dr. Manion and Dr. Cawkwell received grants of stock options and RSUs coinciding with their start of employment. For all NEOs, the grants were apportioned 70% to stock options and 30% to RSUs, with the number of shares underlying the RSUs being further divided by 1.5 to reflect the full value nature of the RSUs.
The following table sets forth the number of shares of common stock issuable upon exercise of the stock options, and the number of shares of common stock underlying the RSUs, granted to our NEOs in 2022:
|
| Number of |
| |
| |
| | Stock Options | | | | Number of RSUs |
| | Granted | | Exercise Price | | Granted |
Name |
| (#) | | ($) | | (#) |
Neal Walker |
| 336,100 |
| 14.94 |
| 96,000 |
Frank Ruffo |
| 155,200 |
| 14.94 |
| 44,300 |
Joseph Monahan |
| 153,100 |
| 14.94 |
| 43,700 |
Douglas Manion |
| 217,800 |
| 13.62 |
| 62,300 |
Gail Cawkwell |
| 210,000 |
| 13.83 | | 60,000 |
Severance and Change of Control Benefits
Our NEOs are entitled to certain benefits if the executive’s employment terminates in certain circumstances or if a change of control occurs. The terms of these arrangements and the amounts payable under them are described below for each NEO under “Compensation Tables—Potential Payments Upon Termination or Change of Control.” We provide these benefits because we believe that severance protection is necessary to attract executives to join our company, as well as to help our executives focus on the best interests of the Company when performing their duties and when making strategic decisions about a potential corporate transaction or change of control.
In November 2022, we entered into a letter agreement with Dr. Walker under which his resignation became effective as of December 31, 2022 and he transitioned to chair of our Board of Directors effective January 1, 2023. Pursuant to such agreement, we agreed that all of his options would continue to vest in accordance with their terms during calendar years 2023 and 2024, and all of his RSUs would continue to vest in accordance with their terms during calendar year 2023, contingent on his continuous service as a member of our Board of Directors. Dr. Walker also remained eligible to receive an annual bonus for 2022. Dr. Walker became eligible to receive cash compensation pursuant to our non-employee director compensation policy beginning January 1, 2023, but will not be eligible to receive any equity compensation pursuant to such policy during calendar year 2023.
In December 2022, we entered into a separation agreement and general release (the “Separation Agreement”) with Mr. Ruffo under which his resignation became effective as of December 31, 2022. Pursuant to such agreement, we agreed to
36
enter into a consulting agreement with Mr. Ruffo, for a term beginning on January 1, 2023, and ending on March 2, 2023 (unless terminated earlier by the parties) under which his equity awards would continue to vest in accordance with their terms and receive a $25,000 consulting fee. In addition, we agreed that all of his then-vested options would remain exercisable until December 31, 2023. Mr. Ruffo also remained eligible to receive an annual bonus for 2022.
Benefits
We maintain a tax-qualified retirement plan (our 401(k) plan) that provides eligible U.S. employees with an opportunity to save for retirement on a tax advantaged basis, up to limits prescribed by applicable law. Currently, we match each eligible employee’s contributions up to 4% of total eligible compensation. Employees are immediately and fully vested in their contributions and our matching contribution.
Our NEOs are eligible to participate in all benefit plans offered to our employees, including our medical, dental, vision, group life and disability insurance plans. Our NEOs accrue more vacation time each pay period than other employees. We do not otherwise provide perquisites or personal benefits to our NEOs.
Prohibition on Hedging and Pledging
Our insider trading policy prohibits directors, officers, and other employees from engaging in short sales, transactions in put or call options, hedging transactions, margin accounts, pledging or other inherently speculative transactions with respect to our stock at any time.
Tax and Accounting Considerations
The Compensation Committee and management consider individual and corporate tax consequences, as well as the accounting impact, of the compensation plans prior to making changes.
Under Section 162(m) of the Internal Revenue Code of 1986, as amended, a company will generally not be entitled to a tax deduction for individual compensation over $1 million that is paid to certain executive officers. As in effect prior to its recent amendment by the Tax Cuts and Jobs Act of 2017, Section 162(m) provided an exception to the deductibility limitations for performance-based compensation that met certain requirements. While considering the impact of Section 162(m) and awarding certain elements of compensation that, at the time, were intended to qualify as performance-based compensation, the Compensation Committee did not adopt a policy requiring all compensation to be fully deductible under Section 162(m). As Section 162(m) has been amended, effective for taxable years beginning after December 31, 2017, the “performance-based” compensation exception was eliminated from Section 162(m), except for certain grandfathered arrangements under the transition rules. The Compensation Committee will continue to consider the potential impact of the application of Section 162(m) on compensation for our executive officers and reserves the right to provide compensation to executive officers that may not be tax-deductible, as well as the right to modify compensation that was initially intended to qualify as “performance-based” compensation if it believes that taking any such action is in the best interests of our company and stockholders.
We account for equity compensation paid to our employees under the Financial Accounting Standards Board Accounting Standards Codification Topic 718, or ASC 718, which requires us to estimate and record an expense over the service period of the equity award. Our cash compensation is recorded as an expense over the period the compensation is earned. The accounting impact is one of many factors that the Compensation Committee considers in determining the structure and size of our executive compensation programs.
2023 Compensation Actions
The Compensation Committee or Board approved the following items in early 2023 related to NEO compensation. The compensation tables provided below do not take into account any compensation changes made in 2023, but this information is being provided as supplemental disclosure to aid in understanding our recent compensation-related activities.
37
| ● | In connection with Dr. Manion’s promotion to Chief Executive Officer, on January 6, 2023, we entered into an amended and restated employment agreement with Dr. Manion effective as of January 1, 2023. Under his new employment agreement, Dr. Manion receives an annual base salary of $600,000 and is eligible to earn an incentive bonus with a target bonus of up to 55% of his annual base salary. Dr. Manion is eligible for substantially the same benefits and payments that Dr. Walker was previously eligible to receive prior to his resignation in the event of certain qualifying terminations or non-renewal of his employment, as described in further detail below under “Compensation Tables—Potential Payments Upon Termination or Change of Control.” |
| ● | In November 2022, we promoted Kevin Balthaser to Chief Financial Officer effective as of January 1, 2023 and entered into an employment agreement with him that became effective as of January 1, 2023. Pursuant to such agreement, Mr. Balthaser receives an annual base salary of $444,000 and is eligible to earn an incentive bonus with a target bonus of up to 40% of his annual base salary. Mr. Balthaser is eligible for substantially the same benefits and payments that Mr. Ruffo was previously eligible to receive prior to his retirement in the event of certain qualifying terminations or non-renewal of his employment, as described in further detail below under “Compensation Tables—Potential Payments Upon Termination or Change of Control.” |
| ● | In February 2023, the Compensation Committee approved increases to annual base salaries (retroactively effective to January 1, 2023) for Dr. Manion (as described above), Dr. Monahan, and Dr. Cawkwell of $600,000, $468,000 and $490,000, respectively. |
| ● | In February 2023, the Compensation Committee also approved 2023 target bonuses. Dr. Monahan’s and Dr. Cawkwell’s target bonuses remained at 40% of their base salaries. As described above, Dr. Manion’s target bonus was increased from 40% to 55% reflecting his promotion to Chief Executive Officer. |
| ● | In February 2023, Dr. Manion, Dr. Monahan, and Dr. Cawkwell each received annual equity grants consisting of 108,000, 30,000 and 30,000 RSUs, respectively, and stock options to purchase 378,000, 105,000 and 105,000 shares, respectively. All of the awards vest in four equal annual installments, subject to the officer’s continuous service with us as of the applicable vesting date. |
Compensation Risk Assessment
The Compensation Committee reviews our compensation program, including compensation levels, designs, practices, and policies to understand if there are any areas that are likely to promote excessive risk-taking or create risks that have a material adverse effect on the Company. Based on the review, we believe that, through a combination of risk-mitigating features and incentives guided by relevant market practices and Company-wide goals, our compensation policies, programs, and practices do not create risks that are reasonably likely to have a material adverse effect on the Company. The following features are noted as strong mitigating features:
| ● | we provide a balance of fixed and performance-based compensation; |
| ● | our short-term incentive plan is based on a variety of corporate goals; |
| ● | the Compensation Committee has discretion to reduce or eliminate a payout under our annual cash incentive plan; |
| ● | our long-term incentive grants vest over time, generally over four years of continuous service; |
| ● | we have a prohibition on hedging and pledging of our stock; |
| ● | we have an independent Compensation Committee; and |
| ● | the Compensation Committee engages with an independent compensation consultant. |
COMPENSATION TABLES
Summary Compensation Table
The following table presents the compensation awarded to or earned by each of our NEOs for the years ended December 31, 2022, 2021 and 2020.
38
Name and Principal Position | | Year | | Salary | | Bonus | | Stock Awards | | Option Awards | | Non-Equity Incentive Plan Compensation | | All Other Compensation | | Total |
Neal Walker(*) | | 2022 | | 589,680 | | - | | 1,434,240 | | 3,446,799 | | 353,808 | | 12,200 | (3) | 5,836,727 |
Former Chief Executive Officer | | 2021 | | 566,500 | | - | | 1,758,786 | | 4,130,564 | | 387,486 | | 11,600 | (3) | 6,854,936 |
| | 2020 | | 423,784 | | - | | 535,830 | | 231,784 | | 407,880 | | 11,400 | (3) | 1,610,678 |
Frank Ruffo(**) | | 2022 | | 417,768 | | - | | 705,644 | (8) | 1,871,960 | (9) | 167,107 | | 12,200 | (3) | 3,174,679 |
Former Chief Financial Officer | | 2021 | | 401,700 | | - | | 798,792 | | 1,873,125 | | 177,551 | | 11,600 | (3) | 3,262,768 |
| | 2020 | | 390,000 | | - | | 125,453 | | 105,356 | | 179,400 | | 11,400 | (3) | 811,609 |
Joseph Monahan(4) | | 2022 | | 420,000 | | - | | 652,878 | | 1,570,083 | | 168,000 | | 12,021 | (3) | 2,822,982 |
Chief Scientific Officer | | 2021 | | 350,000 | | - | | 4,812,000 | | - | | 154,700 | | 10,605 | (3) | 5,327,305 |
Douglas Manion(5) | | 2022 | | 204,167 | | - | | 848,526 | | 2,067,346 | | 82,159 | | - | | 3,202,198 |
President and Chief Operating Officer | | | | | | | | | | | | | | | | |
Gail Cawkwell(6) | | 2022 | | 247,273 | | 25,000 | (7) | 896,400 | | 2,030,642 | | 98,893 | | - | | 3,298,208 |
Chief Medical Officer | | | | | | | | | | | | | | | | |
(*) Dr. Walker resigned as our Chief Executive Officer effective as of December 31, 2022.
(**) Mr. Ruffo retired as our Chief Financial Officer effective as of December 31, 2022.
| (1) | The amounts reflect the full grant date fair value for RSU and stock option awards granted during the indicated year. The grant date fair value was computed in accordance with ASC Topic 718, Compensation—Stock Compensation. The assumptions we used in valuing stock options and restricted stock unit awards are described in Note 9 to our audited financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022. |
| (2) | The amounts reflect the portion of each officer’s target annual bonus paid based on the achievement of our corporate and individual goals, as applicable, which for 2022 are discussed further above under “Compensation Program and Decisions—Annual Bonus (Non-Equity Incentive Plan Compensation).” |
| (3) | The amount consists of company matching contributions to the executive's 401(k) plan account. |
| (4) | Dr. Monahan was not an NEO for the year ended December 31, 2020 and, accordingly, only his compensation for the years ended December 31, 2022 and 2021 is included in the Summary Compensation Table in accordance with SEC rules. |
| (5) | Dr. Manion’s employment with us began in August 2022. |
| (6) | Dr. Cawkwell’s employment with us began in June 2022. |
| (7) | The amount reflects Dr. Cawkwell’s signing bonus. A prorated portion of such bonus is repayable to the Company if Dr. Cawkwell is terminated by us for cause, or if she resigns without good reason, in either case before June 27, 2023. |
| (8) | Amounts reported include $43,802 in incremental fair value recognized as a result of the December 2022 modification of Mr. Ruffo’s March 2022 RSUs, which allowed for continued vesting as a non-officer of the Company. |
39
| (9) | Amounts reported include an aggregate of $280,341 in incremental fair value recognized as a result of the December 2022 modification of Mr. Ruffo’s March 2021, March 2020, February 2018, December 2016, December 2015, September 2015, December 2014 and August 2014 options awards, which extended the post-termination exercise period until December 31, 2023. Although Mr. Ruffo’s March 2022 option award was similarly amended in December 2022 to allow for continued vesting as a non-officer of the Company, there was no incremental fair value associated with such amendment, which is further described under “Grants of Plan-Based Awards” below. |
Grants of Plan-Based Awards
The following table shows certain information regarding grants of plan-based awards to our NEOs during the year ended December 31, 2022:
| | | | | | | | All Other | | All Other | | | | | |
| | | | | | | | Stock | | Option | | | | | |
| | | | | | | | Awards: | | Awards: | | | | Grant Date |
|
| | | | | | | | Number of | | Number of | | Exercise or | | Fair Value of |
|
| | | | Estimated Future Payouts | | Shares of | | Securities | | Base Price | | Stock and |
| ||
| | | | Under Non-Equity Incentive | | Stock or | | Underlying | | of Option | | Option |
| ||
| | | | Plan Awards(1) |
| Units |
| Options | | Awards | | Awards | | ||
Name |
| Grant Date or Modification Date |
| Target ($) |
| Maximum ($) |
| (#)(2) |
| (#)(3) |
| ($/Sh) |
| ($)(4) | |
Neal Walker | | |
| 353,808 | | 495,331 | | | | | | | | | |
|
| 3/1/2022 | | | | |
| | | 336,100 | | 14.94 | | 3,446,799 | (5) |
|
| 3/1/2022 |
| | | | | 96,000 | | | | | | 1,434,240 | (5) |
Frank Ruffo |
| |
| 167,107 | | 217,239 |
| | | | | | | | |
|
| 3/1/2022 |
| | | |
| | | 155,200 | | 14.94 | | 1,591,619 | (6) |
|
| 3/1/2022 |
| | | | | 44,300 | | | | | | 705,644 | (7) |
| | 12/9/2022 | (*) | | | | | | | 49,439 | | 28.68 | | 49,786 | (8) |
| | 12/9/2022 | (*) | | | | | | | 62,400 | | 28.92 | | 62,268 | (9) |
| | 12/9/2022 | (*) | | | | | | | 54,000 | | 22.09 | | 66,412 | (10) |
| | 12/9/2022 | (*) | | | | | | | 7,231 | | 0.72 | | 119 | (11) |
| | 12/9/2022 | (*) | | | | | | | 20,289 | | 1.52 | | 709 | (12) |
| | 12/9/2022 | (*) | | | | | | | 58,080 | | 1.26 | | 1,670 | (13) |
| | 12/9/2022 | (*) | | | | | | | 29,000 | | 24.06 | | 34,025 | (14) |
| | 12/9/2022 | (*) | | | | | | | 65,416 | | 10.66 | | 65,352 | (15) |
| | | | | | | | | | | | | | | |
Joseph Monahan |
| |
| 168,000 | | 218,400 |
| | | | | | | | |
|
| 3/1/2022 |
| | | | | | | 153,100 | | 14.94 | | 1,570,083 | |
| | 3/1/2022 | | | | | | 43,700 | | | | | | 652,878 | |
Douglas Manion | | |
| 82,159 | | 106,807 |
| | | | | | | | |
|
| 8/1/2022 |
| | | |
| | | 217,800 | | 13.62 | | 2,067,346 | |
|
| 8/1/2022 |
| | | | | 62,300 | | | | | | 848,526 | |
Gail Cawkwell | | |
| 98,893 | | 128,561 |
| | | | | | | | |
|
| 7/1/2022 |
| | | |
| | | 210,000 | | 13.83 | | 2,030,642 | |
|
| 7/1/2022 |
| | | | | 60,000 | | | | | | 896,400 | |
(*) Indicates an award modified in 2022 that was not otherwise also originally granted in 2022.
| (1) | Amounts represent cash bonus opportunities provided to NEOs in 2022 under our annual bonus program. There are no threshold payouts, as partially met goals can receive a score based on the partial achievement. Target payment amounts assume goal attainment of 100% of the corporate and individual (as applicable) performance goals. Maximum payment amounts assume goal attainment of 140% of corporate performance goals and 100% of individual goals (as applicable). The criteria used to determine the amount of the annual bonus payable to each NEO for 2022 is described above under “Compensation Programs and Decisions—Annual Bonus (Non-Equity Incentive Plan Compensation).” The actual amounts earned for 2022 are disclosed in the “Non-Equity Incentive Plan Compensation” column of the Summary Compensation Table. |
| (2) | These RSUs vest over four years in four equal installments beginning on the first anniversary of the grant date. |
40
| (3) | These stock options vest over four years in four equal installments beginning on the first anniversary of the grant date. |
| (4) | The grant date fair value and, as applicable, the incremental fair value of equity awards modified in 2022, was computed in accordance with ASC Topic 718, Compensation—Stock Compensation. The assumptions we used in valuing stock options and restricted stock unit awards are described in Note 9 to our audited financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022. |
| (5) | In November 2022, Dr. Walker’s March 2022 option and RSU awards were modified to allow for continued vesting as a non-officer. There was no incremental fair value associated with such amendment. |
| (6) | In December 2022, Mr. Ruffo’s March 2022 option award was modified to allow for continued vesting as a non-officer. There was no incremental fair value associated with such amendment. |
| (7) | In December 2022, Mr. Ruffo’s March 2022 RSU award was modified to allow for continued vesting as a non-officer. The incremental fair value associated with such amendment was $43,802. |
| (8) | Represents the shares of common stock subject to Mr. Ruffo’s December 2015 option grant that were modified by extending the exercise period of the options pursuant to Mr. Ruffo’s Separation Agreement, and the incremental fair value, computed in accordance with ASC 718, associated with the modification of the options. |
| (9) | Represents the shares of common stock subject to Mr. Ruffo’s December 2016 option grant that were modified by extending the exercise period of the options pursuant to Mr. Ruffo’s Separation Agreement, and the incremental fair value, computed in accordance with ASC 718, associated with the modification of the options. |
| (10) | Represents the shares of common stock subject to Mr. Ruffo’s February 2018 option grant that were modified by extending the exercise period of the options pursuant to Mr. Ruffo’s Separation Agreement, and the incremental fair value, computed in accordance with ASC 718, associated with the modification of the options. |
| (11) | Represents the shares of common stock subject to Mr. Ruffo’s August 2014 option grant that were modified by extending the exercise period of the options pursuant to Mr. Ruffo’s Separation Agreement, and the incremental fair value, computed in accordance with ASC 718, associated with the modification of the options. |
| (12) | Represents the shares of common stock subject to Mr. Ruffo’s December 2014 option grant that were modified by extending the exercise period of the options pursuant to Mr. Ruffo’s Separation Agreement, and the incremental fair value, computed in accordance with ASC 718, associated with the modification of the options. |
| (13) | Represents the shares of common stock subject to Mr. Ruffo’s March 2020 option grant that were modified by extending the exercise period of the options pursuant to Mr. Ruffo’s Separation Agreement, and the incremental fair value, computed in accordance with ASC 718, associated with the modification of the options. |
| (14) | Represents the shares of common stock subject to Mr. Ruffo’s March 2021 option grant that were modified by extending the exercise period of the options pursuant to Mr. Ruffo’s Separation Agreement, and the incremental fair value, computed in accordance with ASC 718, associated with the modification of the options. |
| (15) | Represents the shares of common stock subject to Mr. Ruffo’s September 2015 option grant that were modified by extending the exercise period of the options pursuant to Mr. Ruffo’s Separation Agreement, and the incremental fair value, computed in accordance with ASC 718, associated with the modification of the options. |
41
Outstanding Equity Awards as of December 31, 2022
The following table provides information about outstanding equity awards held by each of our NEOs as of December 31, 2022:
| | Option Awards | | Stock Awards | ||||||||||
| | | | | | | | | | | | | | Market |
|
| |
| | | | | |
| |
| Number | | Value |
|
| | | | | | | |
| |
| of Shares | | of Shares |
| | | | | | | | | | |
| of Stock | | of Stock |
| | | | Number of Securities Underlying | | Option | | |
| That | | That | ||
| | Type | | Unexercised Options | | Exercise | | Option |
| Have Not | | Have Not | ||
| | of | | (#) | | Price | | Expiration |
| Vested | | Vested | ||
Name |
| Award |
| Exercisable |
| Unexercisable |
| ($) |
| Date |
| (#) |
| ($)(19) |
Neal Walker |
| Option | | 43,548 | | — | | 0.72 | | 8/12/2024 | | | | |
|
| Option | | 118,840 | | — | | 1.52 | | 12/7/2024 | | | | |
|
| Option | | 211,019 | | — | | 10.66 | | 8/31/2025 | | | | |
|
| Option | | 137,335 | | — | | 28.68 | | 12/17/2025 | | | | |
|
| Option | | 145,600 | | — | | 28.92 | | 12/14/2026 | | | | |
|
| Option | | 151,200 | | — | | 22.09 | | 1/31/2028 | | | | |
|
| Option | | 127,776 | | 127,776 | (1) | 1.26 | | 3/1/2030 | | | | |
|
| Option | | 63,950 | | 191,850 | (2) | 24.06 | | 2/28/2031 | | | | |
|
| Option | | — | | 336,100 | (3) | 14.94 | | 2/29/2032 | | | | |
|
| RSU | | | | | | | | | | 96,150 | (4) | 1,514,363 |
|
| RSU | | | | | | | | | | 54,825 | (5) | 863,494 |
|
| RSU | | | | | | | | | | 96,000 | (6) | 1,512,000 |
| | RSU | | | | | | | | | | 36,508 | (7) | 575,001 |
Frank Ruffo |
| Option | | 7,231 | | — | | 0.72 | | 8/12/2024 | | | | |
|
| Option | | 20,289 | | — | | 1.52 | | 12/7/2024 | | | | |
|
| Option | | 65,416 | | — | | 10.66 | | 8/31/2025 | | | | |
|
| Option | | 49,439 | | — | | 28.68 | | 12/17/2025 | | | | |
|
| Option | | 62,400 | | — | | 28.92 | | 12/14/2026 | | | | |
|
| Option | | 54,000 | | — | | 22.09 | | 1/31/2028 | | | | |
|
| Option | | 58,080 | | 58,080 | (8) | 1.26 | | 3/1/2030 | | | | |
|
| Option | | 29,000 | | 87,000 | (9) | 24.06 | | 2/28/2031 | | | | |
|
| Option | | — | | 155,200 | (10) | 14.94 | | 2/29/2032 | | | | |
|
| RSU | | | | | | | | | | 25,750 | (4) | 405,563 |
|
| RSU | | | | | | | | | | 16,595 | (11) | 261,371 |
|
| RSU | | | | | | | | | | 24,900 | (12) | 392,175 |
| | RSU | | | | | | | | | | 44,300 | (13) | 697,725 |
Joseph Monahan |
| Option | | 56,000 | | — | | 25.80 | | 8/31/2027 | | | | |
|
| Option | | 14,700 | | — | | 22.09 | | 1/31/2028 | | | | |
|
| Option | | — | | 153,100 | (14) | 14.94 | | 2/29/2032 | | | | |
|
| RSU | | | | | | | | | | 13,750 | (4) | 216,563 |
|
| RSU | | | | | | | | | | 25,000 | (15) | 393,750 |
|
| RSU | | | | | | | | | | 150,000 | (16) | 2,362,500 |
| | RSU | | | | | | | | | | 43,700 | (14) | 688,275 |
Douglas Manion | | Option | | — | | 217,800 | (17) | 13.62 | | 7/31/2032 | | | | |
|
| RSU | | | | | | | | | | 62,300 | (17) | 981,225 |
Gail Cawkwell | | Option | | — | | 210,000 | (18) | 13.83 | | 6/30/2032 | | | | |
|
| RSU | | | | | | | | | | 60,000 | (18) | 945,000 |
| (1) | Of the unvested stock options, one-half vested on March 2, 2023, and the remainder will vest on March 2, 2024, subject to Dr. Walker’s continued service as a director. |
| (2) | These stock options were originally scheduled to vest in four equal annual installments beginning on March 1, 2022, subject to Dr. Walker’s continued service. Pursuant to the letter agreement dated November 22, 2022 (the “Letter Agreement”), these stock options will continue to vest in accordance with their terms during calendar years 2023 and 2024, such that 63,950 of the unvested options will not be eligible to vest. |
| (3) | These stock options were originally scheduled to vest in four equal annual installments beginning on March 1, 2023 subject to Dr. Walker’s continued service as an officer. Pursuant to the Letter Agreement, these stock options will |
42
| continue to vest in accordance with their terms during calendar years 2023 and 2024, subject to Dr. Walker’s continued service as a director, such that 168,050 of the unvested options will not be eligible to vest. |
| (4) | These unvested RSUs vested on March 1, 2023. |
| (5) | These unvested RSUs were originally scheduled to vest in three equal installments on March 1, 2023, March 1, 2024 and March 1, 2025, subject to Dr. Walker’s continued service. Pursuant to the Letter Agreement, these RSUs will continue to vest in accordance with their terms during calendar year 2023, such that 36,550 of the unvested RSUs will not be eligible to vest. |
| (6) | These unvested RSUs were originally scheduled to vest in four equal installments on March 1, 2023, March 1, 2024, March 1, 2025 and March 1, 2026, subject to Dr. Walker’s continued service as an officer. Pursuant to the Letter Agreement, these RSUs will continue to vest in accordance with their terms during calendar year 2023, subject to Dr. Walker’s continued service as a director, such that 72,000 of the unvested RSUs will not be eligible to vest. |
| (7) | These unvested RSUs were originally scheduled to vest in two equal installments on March 2, 2023 and March 2, 2024, subject to Dr. Walker’s continued service. Pursuant to the Letter Agreement, these RSUs will continue to vest in accordance with their terms during calendar year 2023, such that 18,254 of the unvested RSUs will not be eligible to vest. |
| (8) | Of the unvested stock options, one-half vested on March 2, 2023, and the remainder will not vest as a result of Mr. Ruffo’s retirement. |
| (9) | Of the unvested stock options, one-third vested on March 1, 2023, and the remainder will not vest as a result of Mr. Ruffo’s retirement. |
| (10) | Of the unvested stock options, one-fourth vested on March 1, 2023, and the remainder will not vest as a result of Mr. Ruffo’s retirement. |
| (11) | Of the unvested RSUs, one-half vested on March 2, 2023, and the remainder will not vest as a result of Mr. Ruffo’s retirement. |
| (12) | Of the unvested RSUs, one-third vested on March 1, 2023, and the remainder will not vest as a result of Mr. Ruffo’s retirement. |
| (13) | Of the unvested RSUs, one-fourth vested on March 1, 2023, and the remainder will not vest as a result of Mr. Ruffo’s retirement. |
| (14) | Of the unvested stock options and RSUs, as applicable, one-fourth vested on March 1, 2023 and the remainder will vest in three equal installments on March 1, 2024, March 1, 2025, and March 1, 2026, subject to the officer’s continued service as an officer through each applicable vesting date. |
| (15) | Of the unvested RSUs, one-half vested on March 2, 2023 and the remainder will vest on March 2, 2024, subject to the officer’s continued service through each applicable vesting date. |
| (16) | Of the unvested RSUs, one-third vested on March 1, 2023 and the remainder will vest in two equal installments on March 1, 2024 and March 1, 2025, subject to the officer’s continued service through each applicable vesting date. |
| (17) | These unvested stock options and RSUs will vest in four equal installments on August 1, 2023, August 1, 2024, August 1, 2025 and August 1, 2026, subject to the officer’s continued service through each applicable vesting date. |
| (18) | These unvested stock options and RSUs will vest in four equal installments on July 1, 2023, July 1, 2024, July 1, 2025 and July 1, 2026, subject to the officer’s continued service through each applicable vesting date. |
43
| (19) | Based on the closing price of our common stock of $15.75 per share on December 31, 2022. |
Option Exercises and Stock Vested
The following table shows certain information regarding RSUs that vested during the year ended December 31, 2022 for our NEOs. There were no option exercises by our NEOs during 2022.
| Stock Awards | ||
| Number of |
| |
| Shares | | |
| Acquired on | | Value Realized on |
| Vesting | | Vesting |
Name | (#) |
| ($)(1) |
Neal Walker | 143,479 | | 2,119,518 |
Frank Ruffo | 46,222 | | 683,096 |
Joseph Monahan | 77,300 | | 1,159,709 |
Douglas Manion | — | | — |
Gail Cawkwell | — | | — |
| (1) | Computed by multiplying the closing market price of our common stock on the vesting date by the number of RSUs subject to such award vesting on the applicable vesting date. |
Potential Payments Upon Termination or Change of Control
Employment Agreements
We have entered into employment agreements with each of our NEOs. Under these agreements, which were in effect as of December 31, 2022, each of them was eligible to receive severance benefits in specified circumstances. As described above, in January 2023 we entered into an amended employment agreement with Dr. Manion in connection with his promotion to Chief Executive Officer.
Severance Upon Qualifying Termination Unrelated to a Change of Control
Each employment agreement provides for payments in the event the executive’s employment is terminated due to death or “Disability”, in the event we terminate the executive’s employment “Without Cause,” if the executive resigns for “Good Reason” (each as defined below), or if the executive’s employment is terminated upon non-renewal by the Company, provided that the executive executes and does not revoke a release of claims (each, a “Qualifying Termination”).
In the event of a Qualifying Termination, each executive would receive the following severance benefits:
| ● | continued payment of then-current base salary for a period of 12 months following termination, in each case payable in accordance with our normal payroll practices; |
| ● | a lump-sum payment of any approved but unpaid bonuses or portion thereof for the preceding year or the year of termination; and |
| ● | a direct payment by the Company to the applicable healthcare provider of 100% of the medical, vision and dental coverage premiums for Dr. Walker and Mr. Ruffo, and the Company’s portion of the medical, vision and dental coverage premiums for Dr. Manion, Dr. Monahan and Dr. Cawkwell, to maintain any COBRA coverage for which he or she is eligible and has appropriately elected for a period of 12 months following termination. |
44
Severance Upon Qualifying Termination Related to a Change of Control
In the event of a Qualifying Termination (other than if the executive’s employment is terminated upon non-renewal by the Company) on or within three months prior to, or within 12 months following, a “Change of Control” (as defined below), each executive would receive the following severance benefits:
| ● | continued payment of then-current base salary for a period of 18 months following termination for Dr. Walker and for a period of 12 months following termination for each of the other NEOs, in each case payable in accordance with our normal payroll practices; |
| ● | a lump-sum payment of any approved but unpaid bonuses or portion thereof for the preceding year or the year of termination; |
| ● | an additional lump sum payment equal to 1.5 times the target bonus for Dr. Walker and the target bonus for each of the other NEOs; |
| ● | a direct payment by the Company to the applicable healthcare provider of 100% of the medical, vision and dental coverage premiums for Dr. Walker and Mr. Ruffo, and the Company’s portion of the medical, vision and dental coverage premiums for Dr. Manion, Dr. Monahan and Dr. Cawkwell, to maintain any COBRA coverage for which he or she is eligible and has appropriately elected for a period of 18 months following termination for Dr. Walker and for a period of 12 months following termination for each of the other NEOs; and |
| ● | if the termination occurs on or within three months prior to the Change of Control, all of his or her unvested stock options and other equity awards outstanding on the effective date of termination would become fully vested on the effective date of the Change of Control, or if the termination occurs within 12 months following the effective date of the Change of Control (provided that any surviving corporation or acquiring corporation assumes his or her stock options or other equity awards, as applicable, or substitutes similar stock options or equity awards for his or her stock options or equity awards, as applicable, in accordance with the terms of the applicable equity incentive plans), all unvested stock options and other equity awards outstanding on the effective date of termination would become fully vested on the date of termination. |
Definitions
With respect to each of our NEOs, the following definitions were adopted in their employment agreements:
| ● | “Cause” means: (i) his or her conviction of, or guilty plea to, a felony, other than traffic violations; (ii) any act or omission by him or her which constitutes gross negligence or a material breach of his or her duty of loyalty; (iii) any material breach by him or her of our personnel policies; (iv) refusal to follow or implement a clear and reasonable directive; (v) breach of fiduciary duty; or (vi) a material violation or breach by him or her of his or her employment agreement, other than an event described in the foregoing clauses, or any other agreement with us; |
| ● | “Good Reason” means, in the absence of events that would support a termination for cause: (i) there is a material failure by us or our successor to pay his or her salary or additional compensation or benefits in accordance with the employment agreement; (ii) his or her annual base salary is materially decreased without his or her prior written consent; (iii) he or she is assigned duties materially inconsistent with his or her title and the responsibilities set forth in his or her job description without his or her prior written consent; (iv) his or her place of employment is changed to a location that is greater than 50 miles from his or her current place of employment (disregarding for this purpose any remote work arrangements); or (v) any other material violation or breach by us of his or her employment agreement; provided, however, none of the above events will constitute good reason absent him or her providing us with proper notice and our failure to cure such event within 30 days of such notice; and |
| ● | “Change of Control” means: (i) our consolidation or merger with or into any other corporation or other entity or person, or any other corporate reorganization, in which our stockholders immediately prior to such consolidation, |
45
| merger or reorganization own, in the aggregate, less than 50% of the surviving entity’s voting power or outstanding capital stock immediately after such consolidation, merger or reorganization, or any transaction or series of related transactions to which we, or any of our stockholders is a party in which greater than 50% of our voting power or outstanding capital stock is transferred, or pursuant to which any person or group of affiliated persons obtains greater than 50% of our voting power or outstanding capital stock, excluding any consolidation or merger effected exclusively to change our domicile; or (ii) any sale, license or other disposition, including through a division or spin-off transaction, of all or substantially all of our assets or any of our subsidiaries’ assets or any sale, exclusive license or other disposition of all or substantially all of our intellectual property; provided, however that neither of the following constitutes a change of control: (A) transfers of capital stock by an existing stockholder as a result of death or otherwise for estate planning purposes or to such stockholder’s affiliates or to any of our other existing stockholders; or (B) issuances of our equity securities in connection with financings for working capital and other general corporate purposes; and, provided further, that such “Change of Control” qualifies as either a change in ownership of the Company as defined in Section 409A of the Code (“Section 409A”) or a change in the ownership of a substantial portion of our assets as defined in Section 409A, as the case may be. |
46
Potential Payments Upon Termination or Change-in-Control Table
The following table shows potential estimated payments that would be made to our NEOs if their employment had terminated in certain instances on December 31, 2022, under contracts or arrangements that were in effect as of December 31, 2022. With respect to equity awards, the calculations assume the closing price of our common stock of $15.75 on December 31, 2022. In addition to the amounts shown in the table below, each executive would receive payments for amounts of base salary and vacation time accrued through the date of termination.
| | | | | |
| | Termination by | | | |
| | Company Without | | Termination by | |
| | Cause, Termination | | Company Without | |
| | by Executive for | | Cause, Termination | |
| | Good Reason, | | by Executive for | |
| | Upon Disability or | | Good Reason, or | |
| | Death Unrelated to a | | Upon Disability or | |
| | Change of Control, | | Death Related to a | |
| | or Upon Nonrenewal by Company | | Change of Control | |
Name |
| ($) |
| ($) | |
Neal Walker(1) | | | | | |
Cash Severance |
| 943,488 | | 1,769,040 | |
Acceleration Value of RSUs |
| — | | 4,464,857 | |
Acceleration Value of Stock Options |
| — | | 2,123,715 | |
Continued Health Coverage |
| 26,428 | | 39,642 | |
Total |
| 969,916 | | 8,397,254 | |
Frank Ruffo(2) | | | | | |
Cash Severance |
| 584,875 | | 751,982 | |
Acceleration Value of RSUs |
| — | | 1,756,834 | |
Acceleration Value of Stock Options |
| — | | 967,291 | |
Continued Health Coverage |
| 20,248 | | 20,248 | |
Total |
| 605,124 | | 3,496,356 | |
Joseph Monahan | | | | | |
Cash Severance |
| 588,000 | | 756,000 | |
Acceleration Value of RSUs |
| — | | 3,661,088 | |
Acceleration Value of Stock Options |
| — | | 124,011 | |
Continued Health Coverage |
| 9,799 | | 9,799 | |
Total |
| 597,799 | | 4,550,897 | |
Douglas Manion | | | | | |
Cash Severance |
| 286,326 | | 482,326 | |
Acceleration Value of RSUs |
| — | | 981,225 | |
Acceleration Value of Stock Options |
| — | | 463,914 | |
Continued Health Coverage |
| 17,791 | | 17,791 | |
Total |
| 304,117 | | 1,945,256 | |
Gail Cawkwell | | | | | |
Cash Severance |
| 346,166 | | 538,166 | |
Acceleration Value of RSUs |
| — | | 945,000 | |
Acceleration Value of Stock Options |
| — | | 403,200 | |
Continued Health Coverage |
| 15,025 | | 15,025 | |
Total |
| 361,191 | | 1,901,391 | |
(1) As described above under “Severance and Change of Control Benefits,” pursuant to his letter agreement with us, in connection with his resignation and transition to chair of our Board of Directors, we agreed to modify certain of Dr. Walker’s options and RSUs, and he received an annual bonus for 2022 of $353,808. Dr. Walker did not receive any of the benefits quantified in the table above in connection with his resignation.
(2) As described above under “Severance and Change of Control Benefits,” pursuant to his Separation Agreement, we entered into a consulting agreement with Mr. Ruffo, for a term beginning on January 1, 2023, and ending on March 2, 2023 under which he continued to vest into his equity awards in accordance with their terms and received a $25,000 consulting fee. We also agreed to modify the post-termination exercise period applicable to Mr. Ruffo’s vested options, and he received an annual bonus for 2022 of $167,107. Mr. Ruffo did not receive any of the benefits quantified in the table above in connection with his resignation.
47
PAY RATIO DISCLOSURE
In accordance with SEC rules, we are providing the ratio of the annual total compensation of Dr. Walker, our Chief Executive Officer during the year ended December 31, 2022, to the median of the annual total compensation of all our employees excluding our Chief Executive Officer (the “Ratio”). For the year ended December 31, 2022, the annual total compensation of our Chief Executive Officer in the Summary Compensation Table is $5,836,727 and the median of the annual total compensation of all of our employees (excluding our Chief Executive Officer) is $190,902. The Ratio is 31 to 1.
In determining the annual total compensation of the median employee, we calculated such employee’s compensation in accordance with SEC executive compensation disclosure rules. This calculation is the same calculation used to determine the total compensation for purposes of the Summary Compensation Table with respect to each of our NEOs.
To identify the median employee, we used the following methodology:
| ● | We collected compensation data from our human resources system of record for all employees, whether employed on a full-time, part-time, temporary or seasonal basis, as of December 31, 2022 which was the last day of our last completed fiscal year. |
| ● | We annualized the compensation of all permanent full-time and part-time employees who we hired during 2022. |
| ● | We used total compensation as of December 31, 2022 as our consistently applied compensation measure. In this context, total compensation meant (1) total base salary (2) all merit and spot bonuses, and (3) the value of all equity awards vested during the year ended December 31, 2022. |
The ratio presented above is a reasonable estimate calculated in a manner consistent with SEC rules based on our human resources system of record. Because the SEC rules for identifying the median employee and calculating the pay ratio allow companies to use different methodologies, exemptions, estimates and assumptions, this pay ratio disclosure may not be comparable to the pay ratio reported by other companies.
48
PAY VERSUS PERFORMANCE
As required by Section 953(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 and Item 402(v) of Regulation S-K, we are providing the following information about the relationship between executive compensation actually paid and certain financial performance of our Company. The disclosure included in this section is prescribed by Securities and Exchange Commission (“SEC”) rules and does not necessarily reflect value actually received or realized by the executives or how our Compensation Committee evaluates compensation decisions in light of Company or individual performance.
Pay Versus Performance Table
The table below presents information on the compensation of our principal executive officer (“PEO”) and our other NEOs (“non-PEO NEOs”) in comparison to certain performance metrics for the years ended December 31, 2022, 2021 and 2020. The metrics are not those that the Compensation Committee uses when setting executive compensation. The use of the term “Compensation Actually Paid” (“CAP”) is required by SEC rules. Neither CAP nor the total amount reported in the Summary Compensation Table (“SCT”) reflect the amount of compensation actually earned or received by or paid to the executives during the applicable year.
| | | | | | | | | | | | Value of Initial Fixed | | | | ||
| | | | | | | Average | | | | $100 Investment Based On: | | | | |||
| | Summary | | | | Summary | | Average | | | | Peer Group | | | | ||
| | Compensation | | Compensation | | Compensation | | Compensation | | Total | | Total | | | | ||
| | Table Total | | Actually | | Total for | | Actually Paid to | | Shareholder | | Shareholder | | | |||
Year |
| for PEO(1)(2) |
| Paid to PEO(1) (3) |
| Non-PEO NEOs(1)(2) |
| Non-PEO NEOs(1) (3) |
| Return(4) |
| Return(5) |
| Net Loss(6) | |||
2022 | | $ | | $ | | | $ | | $ | | $ | | $ | | | $ | ( |
2021 | | $ | | $ | | | $ | | $ | | $ | | $ | | | $ | ( |
2020 | | $ | | $ | | | $ | | $ | | $ | | $ | | | $ | ( |
(1) | For each year shown, the PEO was |
(2) | The amounts shown in this column are the amounts of total compensation reported for Dr. Walker, or the average total compensation reported for the non-PEO NEOs, as applicable, for each corresponding year in the “Total” column of the SCT. Please refer to “Executive Compensation—Compensation Tables—Summary Compensation Table.” |
(3) | The amounts shown have been calculated in accordance with Item 402(v) of Regulation S-K and do not reflect compensation actually realized or received by the Company’s PEO and non-PEO NEOs. In accordance with the requirements of Item 402(v) of Regulation S-K, the following adjustments were made to Dr. Walker’s total compensation, or the average total compensation of the non-PEO NEOs, as applicable, as reported in the “Total” column in the SCT for the applicable year: |
49
|
| 2020 | | 2021 | | 2022 |
PEO SCT Reported Total Compensation | $ | | $ | | $ | |
Aggregate SCT Reported Equity Compensation(a) (-) | $ | | $ | | $ | |
Year-End Fair Value of Awards Granted During the FY & Outstanding (b)(i)(+) | $ | | $ | | $ | |
Year-Over-Year Change in Fair Value of Awards Granted During Prior FY & Outstanding(b)(ii) (+) | $ | | $ | | $ | |
Vesting Date Fair Value of Awards Granted & Vested During the Covered FY(b)(iii) (+) | $ | | $ | - | $ | - |
Year-Over-Year Change in Fair Value of Awards Granted During Prior FY & Vesting During Covered FY(b)(iv) (+) | $ | ( | $ | | $ | |
PEO Compensation Actually Paid Determination | $ | | $ | | $ | |
| | | | | | |
|
| | | | | |
|
| 2020 | | 2021 | | 2022 |
Non-PEO NEOs Average SCT Reported Total Compensation | $ | | $ | | $ | |
Average Aggregate SCT Reported Equity Compensation(a) (-) | $ | | $ | | $ | |
Average Year-End Fair Value of Awards Granted During the FY & Outstanding (b)(i)(+) | $ | | $ | | $ | |
Average Year-Over-Year Change in Fair Value of Awards Granted During Prior FY & Outstanding(b)(ii) (+) | $ | | $ | | $ | |
Average Vesting Date Fair Value of Awards Granted & Vested During the Covered FY(b)(iii) (+) | $ | | $ | - | $ | - |
Average Year-Over-Year Change in Fair Value of Awards Granted During Prior FY & Vesting During Covered FY(b)(iv) (+) | $ | ( | $ | | $ | |
Non-PEO NEOs Average Compensation Actually Paid Determination | $ | | $ | | $ | |
(a) | The reported grant date fair value of equity awards represents the total of the amounts reported for Dr. Walker, or the average of the total amounts reported in the case of the non-PEO NEOs, as applicable, in the “Option Awards” and “Stock Awards” columns in the SCT for the applicable year. |
(b) | The equity award adjustments for each applicable year include the addition (or subtraction, as applicable) of, the following, or the average of the following in the case of the non-PEO NEOs, to the extent applicable: (i) the year-end fair value of any equity awards granted in the applicable year that are outstanding and unvested as of the end of the year; (ii) the amount of change as of the end of the applicable year (from the end of the prior fiscal year) in fair value of any awards granted in any prior year that are outstanding and unvested as of the end of the applicable year; (iii) for awards that are granted and vest in the same applicable year, the fair value as of the vesting date; (iv) for awards granted in any prior year that vested in the applicable year, the amount equal to the change as of the vesting date (from the end of the prior fiscal year) in fair value; (v) for awards granted in any prior year that failed to meet the applicable vesting conditions during the applicable year, a deduction for the amount equal to the fair value at the end of the prior fiscal year; and (vi) the dollar value of any dividends or other earnings paid on stock or option awards in the applicable year prior to the vesting date that are not otherwise reflected in the fair value of such award or included in any other component of total compensation for the applicable year. |
(4) | Cumulative total shareholder return (“TSR”) is calculated by dividing the sum of the cumulative amount of dividends for the measurement period, assuming dividend reinvestment, and the difference between the share price of our common stock at the end and the beginning of the measurement period by the share price of our common stock at the beginning of the measurement period. We have never declared or paid any dividends on our common stock. |
(5) | Represents the weighted peer group TSR, weighted according to the respective companies’ stock market capitalization at the beginning of each period for which a return is indicated. The peer group used for this purpose is the Nasdaq Biotechnology Index. |
(6) | The dollar amounts reported represent the amount of net loss reflected in our audited financial statements for the applicable year. |
50
Analysis of Information Presented in the Pay Versus Performance Table
As described in more detail above in “Executive Compensation–Compensation Discussion and Analysis,” the Company’s executive compensation program reflects a performance-driven compensation philosophy. While the Company utilizes several performance measures to align executive compensation with Company performance, those Company measures are not financial performance measures and are therefore not presented in the Pay Versus Performance table. Moreover, the Company generally seeks to incentivize long-term performance, and therefore does not specifically align the Company’s performance measures with “compensation actually paid” (as computed in accordance with Item 402(v) of Regulation S-K) for a particular year. In accordance with Item 402(v) of Regulation S-K, we are providing the following descriptions of the relationships between information presented in the Pay Versus Performance table above.
Compensation Actually Paid, Cumulative TSR of the Company and Cumulative Peer Group TSR
The following graph illustrates the relationship of the CAP for our PEO and non-PEO NEOs, as calculated pursuant to SEC rules, to our cumulative TSR and the TSR of the Nasdaq Biotechnology Index (“NBI”) over the three years presented in the Pay Versus Performance table.
51
Compensation Actually Paid and Net Loss
The following graph illustrates the relationship of the CAP for our PEO and non-PEO NEOs, as calculated pursuant to SEC rules, to our net loss over the three years presented in the Pay Versus Performance table.
All information provided above under the “Pay Versus Performance” heading will not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing, except to the extent the Company specifically incorporates such information by reference.
52
NON-EMPLOYEE DIRECTOR COMPENSATION
Under our non-employee director compensation policy, we pay each of our non-employee directors a cash retainer for service on the Board and for service on each committee of which the director is a member. The policy applies to each of our directors who is not an employee of our company. During 2022, Dr. Walker was our Chief Executive Officer and did not receive any additional compensation for service as a director. He became eligible to receive compensation under our non-employee director compensation policy on January 1, 2023.
Pursuant to the policy in effect for 2022, each non-employee director receives an annual cash retainer of $40,000 for serving on our Board. The Chair of the Board receives an additional annual cash retainer of $30,000. Effective January 1, 2023, the Lead Independent Director receives an additional annual cash retainer of $25,000. The members of each of the Audit, Compensation, Nominating and Corporate Governance and Research and Development Committees receive additional retainers for such service, as does the Chair of each such committee (in addition to the member retainers), as follows:
|
| | | Additional | |
| | Member | | Chair | |
|
| Annual Service | | Annual Service | |
|
| Retainer | | Retainer | |
Committee | | ($) | | ($) | |
Audit Committee | | 7,500 | | 12,500 | |
Compensation Committee | | 6,000 | (1) | 8,000 | (2) |
Nominating and Corporate Governance Committee | | 4,500 | | 4,500 | |
Research and Development Committee | | 6,000 | | 8,000 | |
| (1) | Effective February 22, 2023, the Board amended the non-employee director compensation policy to increase the annual service retainer for members of the Compensation Committee to $7,500. |
| (2) | Effective January 1, 2023, the Board amended the non-employee director compensation policy to increase the additional annual service retainer for the chair of the Compensation Committee to $12,500. |
All annual cash compensation amounts are payable in equal quarterly installments in arrears, on the last day of each fiscal quarter for which the service occurred, prorated based on the days served in the applicable fiscal quarter.
We also reimburse our non-employee directors for reasonable travel and out-of-pocket expenses incurred in connection with attending our Board and committee meetings.
Each new non-employee director who joins our Board will be granted awards under our 2015 Plan with an aggregate grant date fair value (as calculated for financial reporting purposes) equal to the lesser of (a) $320,000 or (b) the fair value of 22,500 stock options measured as of the date the director joins the Board. Once the aggregate fair value of the new director award has been determined, the new director will be granted a stock option having a grant date fair value equal to 70% of such amount and restricted stock units having a grant date fair value equal to 30% of such amount.
On the date of each annual meeting of our stockholders, each non-employee director who continues to serve as a director of our company following the meeting will be granted awards under our 2015 Plan with an aggregate grant date fair value (as calculated for financial reporting purposes) equal to the lesser of (a) $320,000 or (b) the fair value of 22,500 stock options measured as of the annual meeting date. Once the aggregate fair value of the continuing director award has been determined, the continuing director will be granted a stock option having a grant date fair value equal to 70% of such amount and restricted stock units having a grant date fair value equal to 30% of such amount. In no event, however, shall the fair value of the annual award, together with the fair value of any initial award granted to a new director who joined the Board in the same fiscal year, exceed $320,000 in the aggregate.
The shares subject to each stock option granted will vest in equal monthly installments over 12 months and the restricted stock units will vest in one installment on the first anniversary of the grant date, subject to continued service through the applicable vesting date. The exercise price per share of each stock option will be equal to the closing price of our common
53
stock on the date of the option grant. Each such stock option will have a term of ten years from the date of grant, subject to earlier termination in connection with a termination of the non-employee director’s continuous service with us.
On June 2, 2022, the date of our 2022 annual meeting of stockholders, each non-employee director who continued to serve as a director of our company following the meeting was granted a stock option to purchase 15,750 shares of common stock and 4,507 restricted stock units under our 2015 Plan. These awards are reflected in the table below.
Director Compensation Table
The following table shows the compensation earned by each of our non-employee directors for 2022. Dr. Walker, our Chief Executive Officer in 2022, is also a director but did not receive any additional compensation for his service as a director in 2022. Dr. Walker’s compensation as an executive officer is set forth above under “Executive Compensation—Compensation Tables—Summary Compensation Table.”
| Fees Earned or Paid |
| |
| | | | |
| | in Cash | | Stock Awards | | Option Awards | | Total |
Name |
| ($) | | ($)(1)(2)(3) | | ($)(1)(2)(4) | | ($) |
William Humphries |
| 44,500 | | 65,261 | | 152,293 | | 262,054 |
Anand Mehra, M.D. |
| 60,000 | | 65,261 | | 152,293 | | 277,554 |
Christopher Molineaux |
| 79,000 | | 65,261 | | 152,293 | | 296,554 |
Andrew Powell |
| 52,000 | | 65,261 | | 152,293 | | 269,554 |
Bryan Reasons |
| 60,000 | | 65,261 | | 152,293 | | 277,554 |
Andrew Schiff, M.D. |
| 52,000 | | 65,261 | | 152,293 | | 269,554 |
Maxine Gowen, Ph.D. |
| 67,500 | | 65,261 | | 152,293 | | 285,054 |
Vincent Milano |
| 46,000 | | 65,261 | | 152,293 | | 263,554 |
| (1) | Reflects the aggregate grant date fair value for awards granted for the fiscal year ended December 31, 2022 calculated in accordance with FASB ASC Topic 718. For a discussion of valuation assumptions, see Note 9 to our audited consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022. Our directors will not realize the estimated value of these awards until the awards are vested, exercised and/or sold, as applicable. |
| (2) | As of December 31, 2022, our non-employee directors held the following number of stock options and RSUs: Mr. Humphries, 62,625 stock options and 4,507 RSUs; Dr. Mehra, 44,625 stock options and 4,507 RSUs; Mr. Molineaux, 69,650 stock options and 4,507 RSUs; Mr. Powell, 68,625 stock options and 4,507 RSUs; Mr. Reasons, 52,625 stock options and 4,507 RSUs; Dr. Schiff, 60,625 stock options and 4,507 RSUs; Dr. Gowen, 52,625 stock options and 4,507 RSUs; and Mr. Milano, 58,013 stock options and 4,507 RSUs. |
| (3) | Consists of 4,507 RSUs granted on June 2, 2022. The RSUs will vest on June 2, 2023, subject to continuous service with us through that date. |
| (4) | Consists of an option granted on June 2, 2022 to purchase 15,750 shares at an exercise price of $14.48 per share. This option vests in 12 equal monthly installments through June 2, 2023, subject to continuous service with us through each vesting date. |
54
SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS
The following table provides certain information regarding our equity compensation plans in effect as of December 31, 2022:
|
| |
|
| |
| Number of securities | |
|
| |
|
| |
| remaining available for | |
|
| |
|
| Weighted-average |
| future issuance under | |
|
| Number of securities to |
|
| exercise |
| equity compensation | |
|
| be issued upon exercise |
|
| price of outstanding |
| plans | |
| | of outstanding options, |
|
| options, |
| (excluding securities | |
| | warrants and rights | | | warrants and rights |
| reflected in column (a)) | |
Plan Category | | (a) | | | (b) |
| (c) | |
Equity compensation plans approved by security holders: | | | | | | | | |
2012 Equity Compensation Plan(1) |
| 473,977 |
| $ | 6.91 |
| — | |
2015 Equity Incentive Plan |
| 5,843,317 |
| $ | 12.08 | (2) | 3,095,380 | (3) |
Equity compensation plans not approved by security holders: | | | | | | | | |
2017 Inducement Plan(4) |
| 370,600 |
| $ | 24.31 | | — | |
Total |
| 6,687,894 | | | |
| 3,095,380 | |
| (1) | No additional further options or awards may be granted under the 2012 Equity Compensation Plan. |
| (2) | Weighted average exercise price for the 2015 Plan gives effect to outstanding restricted stock units, which have no exercise price. Excluding the restricted stock units, the weighted average exercise price would be $16.33 per share. |
| (3) | On January 1 of each year, the number of shares reserved under the 2015 Plan is automatically increased by 4% of the total number of shares of common stock that are outstanding at that time, or a lesser number of shares as may be determined by our Board. Pursuant to the terms of the 2015 Plan, an additional 2,667,545 shares were added to the number of available shares reflected in the table effective January 1, 2023. |
| (4) | Our Board adopted the 2017 Inducement Plan, which is a non-stockholder approved stock plan adopted pursuant to the “inducement exception” provided under Nasdaq listing rules. All shares of common stock that were eligible for issuance under the 2017 Inducement Plan after October 1, 2018, including any shares underlying any awards that expire or are otherwise terminated, reacquired to satisfy tax withholding obligations, settled in cash or repurchased by the Company in the future that would have been eligible for re-issuance under the 2017 Inducement Plan, were retired. No additional further options or awards may be granted under the 2017 Inducement Plan; all outstanding stock awards will continue to be governed by their existing terms. |
55
TRANSACTIONS WITH RELATED PERSONS
RELATED PERSON TRANSACTIONS POLICY AND PROCEDURES
We have adopted a related person transactions policy that sets forth our procedures for the identification, review, consideration and approval or ratification of related person transactions. For purposes of our policy only, a related person transaction is a transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which we and any related person are, were or will be participants in which the amount involved exceeds $120,000. Transactions involving compensation for services provided to us as an employee, consultant or director are not covered by this policy. A related person is any executive officer, director or beneficial owner of more than 5% of any class of our voting securities, including any of their immediate family members, and any entity owned or controlled by such persons.
Under the policy, if a transaction has been identified as a related person transaction, including any transaction that was not a related person transaction when originally consummated or any transaction that was not initially identified as a related person transaction prior to consummation, our management must present information regarding the related person transaction to our Audit Committee, or, if Audit Committee approval would be inappropriate, to another independent body of our Board, for review, consideration and approval or ratification. The presentation must include a description of, among other things, the material facts, the interests, direct and indirect, of the related persons, the benefits to us of the transaction and whether the transaction is on terms that are comparable to the terms available to or from as the case may be, an unrelated third party or to or from employees generally. Under the policy, we collect information that we deem reasonably necessary from each director, executive officer and, to the extent feasible, significant stockholder to enable us to identify any existing or potential related person transactions and to effectuate the terms of the policy. In addition, under our Code of Business Conduct and Ethics, our employees and directors have an affirmative responsibility to disclose any potential conflicts of interest. In considering related person transactions, our Audit Committee, or other independent body of our Board, takes into account the relevant available facts and circumstances including, but not limited to:
| ● | the risks, costs and benefits to us; |
| ● | the impact on a director’s independence in the event that the related person is a director, immediate family member of a director or an entity with which a director is affiliated; |
| ● | the terms of the transaction; |
| ● | the availability of other sources for comparable services or products; and |
| ● | the terms available to or from, as the case may be, unrelated third parties or to or from employees generally. |
The policy requires that, in determining whether to approve, ratify or reject a related person transaction, our Audit Committee, or other independent body of our Board, must consider, in light of known circumstances, whether the transaction is in, or is not inconsistent with, our best interests and those of our stockholders, as our Audit Committee, or other independent body of our Board, determines in the good faith exercise of its discretion.
CERTAIN RELATED PERSON TRANSACTIONS
There have been no transactions since January 1, 2022 to which we have been a participant in which the amount involved exceeded or will exceed $120,000 and in which any of our directors, executive officers or holders of more than 5% of our capital stock, or any members of their immediate family, had or will have a direct or indirect material interest, other than compensation arrangements which are described under “Executive Compensation” and “Non-Employee Director Compensation.”
56
Indemnification Agreements
In addition to the compensation arrangements with our directors and executive officers, we have entered into indemnity agreements with each of them which provide, among other things, that we will indemnify such officer or director, under the circumstances and to the extent provided for therein, for expenses, damages, judgments, fines and settlements he or she may be required to pay in actions or proceedings which he or she is or may be made a party by reason of his or her position as our director, officer or other agent, and otherwise to the fullest extent permitted under Delaware law and our bylaws.
57
HOUSEHOLDING OF PROXY MATERIALS
The SEC has adopted rules that permit companies and intermediaries (e.g., brokers) to satisfy the delivery requirements for Notices of Internet Availability of Proxy Materials or other Annual Meeting materials with respect to two or more stockholders sharing the same address by delivering a single Notice of Internet Availability of Proxy Materials or other Annual Meeting materials addressed to those stockholders. This process, which is commonly referred to as “householding,” potentially means extra convenience for stockholders and cost savings for companies.
Brokers with account holders who are our stockholders will be “householding” the Company’s proxy materials. A single Notice of Internet Availability will be delivered to multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. If you have received notice from your broker that they will be “householding” communications to your address, “householding” will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no longer wish to participate in “householding” and would prefer to receive a separate Notice of Internet Availability, please notify your broker or direct your written request to Aclaris Therapeutics, Inc., Attn: Corporate Secretary, 640 Lee Road, Suite 200, Wayne, Pennsylvania 19087. Stockholders who currently receive multiple Notices of Internet Availability at their addresses and would like to request “householding” of their communications should contact their brokers.
58
OTHER MATTERS
The Board of Directors knows of no other matters that will be presented for consideration at the Annual Meeting. If any other matters are properly brought before the meeting, it is the intention of the persons named in the accompanying proxy to vote on such matters in accordance with their best judgment.
| By Order of the Board of Directors |
| |
| |
| Matthew Rothman |
| Secretary |
April 20, 2023
A copy of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed with the Securities and Exchange Commission is available without charge upon written request to: Corporate Secretary, Aclaris Therapeutics, Inc., 640 Lee Road, Suite 200, Wayne, Pennsylvania 19087.
59
Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: KEEP THIS PORTION FOR YOUR RECORDS DETACH AND RETURN THIS PORTION ONLY THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. V04599-P91321 ! ! ! For All Withhold All For All Except For Against Abstain For Against Abstain For Against Abstain ! ! ! ! ! ! ! ! ! ACLARIS THERAPEUTICS, INC. To withhold authority to vote for any individual nominee(s), mark "For All Except" and write the number(s) of the nominee(s) on the line below. ACLARIS THERAPEUTICS, INC. C/O BROADRIDGE P.O. BOX 1342 BRENTWOOD, NY 11717 Nominees: NOTE: Such other business as may properly come before the meeting or any adjournment thereof. 2. To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying this proxy card. 3. To approve an amendment to our Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 100,000,000 shares to 200,000,000 shares. 4. To ratify the selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as the independent registered public accounting firm of Aclaris Therapeutics, Inc. for its fiscal year ending December 31, 2023. Please sign exactly as your name(s) appear(s) hereon. When signing as attorney, executor, administrator, or other fiduciary, please give full title as such. Joint owners should each sign personally. All holders must sign. If a corporation or partnership, please sign in full corporate or partnership name by authorized officer. 1. Election of Directors The Board of Directors recommends you vote FOR the following directors to hold office until the 2026 Annual Meeting: The Board of Directors recommends you vote FOR the following proposal: The Board of Directors recommends you vote FOR the following proposal: The Board of Directors recommends you vote FOR the following proposal: 01) Anand Mehra, M.D. 02) Andrew Powell, Esq. 03) Maxine Gowen, Ph.D. VOTE BY INTERNET Before The Meeting - Go to www.proxyvote.com or scan the QR Barcode above Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 p.m. Eastern Time the day before the cut-off date or meeting date. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an electronic voting instruction form. During The Meeting - Go to www.virtualshareholdermeeting.com/ACRS2023 You may attend the meeting via the Internet and vote during the meeting. Have the information that is printed in the box marked by the arrow available and follow the instructions. VOTE BY PHONE - 1-800-690-6903 Use any touch-tone telephone to transmit your voting instructions up until 11:59 p.m. Eastern Time the day before the cut-off date or meeting date. Have your proxy card in hand when you call and then follow the instructions. VOTE BY MAIL Mark, sign and date your proxy card and return it in the postage-paid envelope we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717. SCAN TO VIEW MATERIALS & VOTEw |
V04600-P91321 ACLARIS THERAPEUTICS, INC. Annual Meeting of Stockholders June 1, 2023 9:00 AM This proxy is solicited by the Board of Directors The stockholder hereby appoints Douglas Manion, Kevin Balthaser and Matthew Rothman, or any of them, as proxies, each with the power to appoint his substitute, and hereby authorizes them to represent and to vote, as designated on the reverse side of this ballot, all of the shares of common stock of ACLARIS THERAPEUTICS, INC. that the stockholder is entitled to vote at the Annual Meeting of Stockholders to be held at 9:00 AM, Eastern Time on June 1, 2023, live via webcast at www.virtualshareholdermeeting.com/ACRS2023 and any adjournment or postponement thereof. This proxy, when properly executed, will be voted in the manner directed herein. If no such direction is made, this proxy will be voted in accordance with the Board of Directors' recommendations. Continued and to be signed on reverse side Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting: The Notice and Proxy Statement and 2022 Annual Report are available at www.proxyvote.com. |